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neutrophils and monocytes into inflamed colon. Myeloid HIF ablation also hinders macrophage functional
conversion to a protective, pro-resolving phenotype, and elevates gut serum amyloid A levels during the
resolution phase of colitis. These data suggest that myeloid HIF signaling promotes the effective resolution of
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Second, the effect of HIF inhibition in colitis-associated cancer (CAC) and other inflammatory diseases is
studied using myeloid-specific depletion of each HIF-α subunit or panHIF. Myeloid HIF deficiency elevates
tumor burden and advances disease progression of murine CAC. Acute skin inflammation is slightly mitigated
upon loss of myeloid ARNT. However, myeloid HIFs are dispensable for leukocyte influx in a peritonitis
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ABSTRACT 
HYPOXIC INFLUENCES ON MYELOID CELLS DURING INFLAMMATION AND 
INFLAMMATION-ASSOCIATED CANCER 
Nan Lin 
M. Celeste Simon 
Hypoxia is a prominent characteristic of many acute or chronic inflammatory diseases, 
and exerts significant influence on their progression. Macrophages and neutrophils are major 
cellular components of innate immunity and contribute not only to O2 deprivation at the site of 
inflammation, but also alter many of their functions in response to hypoxia to either facilitate or 
suppress inflammation. Hypoxia stabilizes HIF-αs in macrophages and neutrophils, and these O2-
sensitive transcription factors are key regulators of inflammatory responses in myeloid cells. This 
body of work investigates the role of myeloid HIF-αs in the settings of several acute and chronic 
inflammatory diseases.  
First, the role of pan-HIF signaling in acute intestinal inflammation is investigated by 
depleting myeloid ARNT, the obligate heterodimeric binding partner for both HIF-α subunits, in a 
dextran sodium sulfide-induced murine acute colitis model. Myeloid pan-HIF deficiency 
exacerbates infiltration of pro-inflammatory neutrophils and monocytes into inflamed colon. 
Myeloid HIF ablation also hinders macrophage functional conversion to a protective, pro-resolving 
phenotype, and elevates gut serum amyloid A levels during the resolution phase of colitis. These 
data suggest that myeloid HIF signaling promotes the effective resolution of acute colitis.  
Second, the effect of HIF inhibition in colitis-associated cancer (CAC) and other 
inflammatory diseases is studied using myeloid-specific depletion of each HIF-α subunit or pan-
HIF. Myeloid HIF deficiency elevates tumor burden and advances disease progression of murine 
CAC. Acute skin inflammation is slightly mitigated upon loss of myeloid ARNT. However, myeloid 
HIFs are dispensable for leukocyte influx in a peritonitis model and animal survival in an 
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endotoxemia model. Collectively, these data suggest that HIF-αs adopt diverse roles during 
inflammation, and their functions highly depend on specific types and stages of disease.   
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CHAPTER 1 
Introduction 
This chapter has been adapted from the following review article: Lin, N. and Simon, M.C. (2016). 
Hypoxia-inducible factors: key regulators of myeloid cells during inflammation. J Clin Invest. 
2016;126(10):3661-3671. https://doi.org/10.1172/JCI84426. 
 
INFLAMMATION AND HYPOXIA 
Inflammation constitutes the body’s defensive response to injury and/or infection 
in order to eliminate pathogens and damaged tissue, while initiating tissue repair and 
healing. Upon tissue injury or pathogen invasion, local sentinel cells such as resident 
macrophages and mast cells respond to dilate blood vessels, increase vascular 
permeability, and recruit a variety of leukocytes to the site of inflammation. During the 
acute phase of inflammatory responses, a major task of such recruited cells is the 
clearance of damaged tissue or pathogens. Upon transition into the resolution phase, 
tissue homeostasis is gradually restored. If acute inflammation fails to subside, it 
progresses into chronic inflammation with potentially serious consequences for the 
afflicted patient (Nathan and Ding 2010, Fullerton and Gilroy 2016). One feature of 
inflammation sites is low oxygen (O2) tension, termed “hypoxia.” Oxygen tension ranges 
between 2.5% and 9% in most healthy tissues. However, poor O2 availability resulting 
from damaged vasculature, high metabolic rates of bacteria and other pathogens, and 
numerous infiltrating immune cells deprive inflamed tissue of O2, frequently leading to 
partial O2 pressures (pO2) of less than 1% (Imtiyaz and Simon 2010, Lewis et al. 1999). 
The interdependence between inflammation and hypoxia has been evident for 
many years. Hypoxia is prevalent in multiple inflammatory scenarios, such as 
inflammatory bowel diseases (IBDs) and rheumatoid arthritis (RA) (Sivakumar et al. 
2 
 
2008, Muz et al. 2009, Colgan and Taylor 2010, Taylor and Colgan 2007). The intestinal 
mucosa exhibits an O2 gradient from crypt to villus, wherein O2 is highest in the crypts 
and lowest in the villus tips, which are closest to the anoxic gut lumen (Zheng, Kelly, and 
Colgan 2015). This “physiological” hypoxia is largely extended with intestinal 
inflammation (Colgan and Taylor 2010, Taylor and Colgan 2007). Hypoxia is also a 
characteristic of inflamed joints in patients with RA. Using a highly sensitive gold 
microelectrode, investigators accurately measured synovial O2 tension in RA patients 
(Sivakumar et al. 2008), demonstrating that RA median O2 tension in synovial tissue 
(2%–4%) was much lower than that in the noninflamed synovium (9%–12%) (Sivakumar 
et al. 2008, Muz et al. 2009). 
Low O2 tension can also directly contribute to inflammation. In the setting of 
obesity, hypoxia develops as adipose tissue mass expands, initiating inflammatory 
responses. Secretion of inflammation-related adipokines (e.g., TNF-α and leptin) 
increases in hypoxic adipose tissue. Together with additional disruptions in glucose and 
lipid metabolism, this inflammation can become chronic and systemic, eventually leading 
to insulin resistance (Ye 2009, Trayhurn 2013).  In the lung, alveolar hypoxia can be 
induced by exposing rats to 10% O2 for up to 8 hours, which triggers macrophage 
recruitment, enhances expression of HIF-1α and inflammatory cytokines (e.g., 
macrophage inflammatory protein 1-α [MIP-1α], monocyte chemoattractant protein-1 
[MCP-1], and TNF-α), promotes NF-κB activity, and elevates albumin leakage 
(Madjdpour et al. 2003). Similar observations were made in mice exposed to 5% O2 for 
60 minutes, where levels of IL-6, TNF-α, and IL-1α were elevated in serum and isolated 
peritoneal macrophages and Kupffer cells (liver macrophages) (Ertel et al. 1995). In 
humans, hypoxia-induced inflammation is evident in individuals with high-altitude illness. 
Those who ascend rapidly are at risk of developing high-altitude pulmonary and cerebral 
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edema, caused by hypoxic pulmonary vasoconstriction, high arterial and capillary 
pressure, and elevated levels of circulating IL-6, IL-1 receptor antagonist (IL-1RA), and 
C-reactive protein (CRP) (Bartsch and Swenson 2013, Hartmann et al. 2000). All of 
these examples indicate that the relationship between inflammation and hypoxia exists 
in many pathological settings, and is a potentially attractive therapeutic target. 
HYPOXIA AND HYPOXIA-INDUCIBLE FACTORS 
In many of the pathological situations described above (He et al. 2011, Lee et al. 2011, 
Madjdpour et al. 2003, Colgan and Taylor 2010, Sivakumar et al. 2008, Taylor and Colgan 2007), 
HIFs are activated in response to the hypoxic and inflammatory microenvironment. HIFs 
represent the primary O2-sensing transcription factors (Majmundar, Wong, and Simon 2010, 
Mucaj, Shay, and Simon 2012, Keith, Johnson, and Simon 2012, Lee and Simon 2015), as 
heterodimers comprised of an O2-sensitive α subunit (HIF-α) and a constitutively expressed β 
subunit (HIF-1β or aryl hydrocarbon receptor nuclear translocator [ARNT]). Three α subunits have 
been discovered thus far: HIF-1α, HIF-2α, and HIF-3α. While HIF-1α and HIF-2α are well 
characterized, relatively little is known about HIF-3α (Kaelin and Ratcliffe 2008, Gu et al. 1998). 
The HIF3A gene encodes multiple HIF-3α variants, which are structurally distinct from HIF-1α and 
HIF-2α, as they lack a C-terminal transactivation domain. Divergence in structure and variant 
diversity allow HIF-3α to have numerous modes of action, regulating a transcriptional program 
that is distinct from that of HIF-1α (Duan 2016). In this chapter, we will focus on HIF-1α and HIF-
2α, but additional details about HIF-3α are reviewed elsewhere (Zhang et al. 2014, Duan 2016, 
Gu et al. 1998). Under normoxia, the O2-sensitive α subunit is hydroxylated on two conserved 
proline residues (P402/P405 and P564/P531 for HIF-1α/HIF-2α, respectively) within the O2-
dependent degradation domain (Kuhl et al.) by prolyl hydroxylase domain–containing proteins 
(PHDs) (Kaelin 2005, Kaelin and Ratcliffe 2008). Hydroxylated HIF-α subunits are then 
polyubiquitinated by the von Hippel-Lindau (VHL) tumor suppressor E3 ubiquitin ligase complex 
and subsequently degraded via the 26S proteasome (Maxwell et al. 1999, Cockman et al. 2000, 
4 
 
Jaakkola et al. 2001). Under hypoxia, PHDs cannot hydroxylate key HIF-α proline residues due to 
limited access to their substrate (O2) or redox imbalance (Chandel et al. 2000, Bell and Chandel 
2007, Lin et al. 2008, Lee and Simon 2015), resulting in HIF-α stabilization. Stabilized HIF-αs 
translocate into the nucleus, dimerize with their obligate binding partner ARNT, recruit additional 
coactivators, and bind to hypoxia-response elements (HREs) to enhance transcription of 
hundreds of genes whose products mediate cellular adaptation to hypoxia. Such pathways 
include metabolism, angiogenesis, and inflammatory responses. 
Other than O2-dependent HIF posttranslational modifications, HIF-α stabilization can be 
induced by inflammatory stimuli independently of hypoxia. The pro-inflammatory cytokines TNF-α 
and IL-1β promote HIF-1α accumulation in an NF-κB–dependent manner (Jung, Isaacs, Lee, 
Trepel, Liu, et al. 2003, Zhou, Schmid, and Brune 2003, Jung, Isaacs, Lee, Trepel, and Neckers 
2003). Bacterial products, such as LPS, can also stabilize HIF-1α under normoxia through 
multiple pathways, such as NF-κB (Fang et al. 2009, Rius et al. 2008), ROS (Nishi et al. 2008), 
PHDs (Peyssonnaux et al. 2007), and MAPKs (Frede et al. 2006). On the other hand, hypoxic 
responses can also be HIF independent. For example, hypoxia suppresses mTOR activity 
independently of HIF signaling (Arsham, Howell, and Simon 2003), via the mTOR inhibitor 
REDD1 and the TSC1/TSC2 complex (Brugarolas et al. 2004). Other hypoxia-responsive 
pathways include endoplasmic reticulum (ER) stress (Koumenis et al. 2002) and NF-κB 
(Cummins et al. 2006, Rius et al. 2008, Safronova et al. 2009) pathways. One myeloid-specific 
example is mentioned later in this chapter (Snodgrass et al. 2016). 
MYELOID CELLS IN INFLAMMATION 
Macrophages are key cellular components of innate immunity and encompass a highly 
heterogeneous population of cells with a broad array of phenotypes and functions. Some of these 
cells are distributed over most of the body, residing in many tissues (e.g., Kupffer cells in the liver, 
osteoclasts in the bone, and microglia in the brain), while others are differentiated monocytes that 
infiltrate sites of inflammation to promote adaptive responses or facilitate restoration of tissue 
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homeostasis (Davies et al. 2013, Davies and Taylor 2015). Upon pathogen invasion or injury, 
tissue-resident macrophages represent the first responders, recruiting neutrophils via secretion of 
chemokines (e.g., IL-8 in humans and CXCL1 in mice). Once neutrophils arrive at the 
compromised site, they release monocyte chemoattractants (e.g., MCP-1) so that large numbers 
of recruited monocytes/macrophages extend the inflammatory response (Wynn, Chawla, and 
Pollard 2013, Ginhoux and Jung 2014, Fournier and Parkos 2012). These macrophages normally 
adopt a pro-inflammatory or “classically activated” (M1) phenotype, which is often induced by 
IFN-γ and Toll-like receptor ligands. M1 macrophages elevate their secretion of reactive oxygen 
and nitrogen species (ROS and NOS) and pro-inflammatory cytokines, to eliminate pathogens 
and damaged tissues while recruiting additional immune effector cells. When most of the 
pathogens or tissue debris are removed, hyperactivation of macrophage bactericidal activity may 
result in unnecessary destruction of healthy tissue. As highly plastic cells, macrophages then 
respond to microenvironmental cues (e.g., TH2-type cytokines IL-4 and IL-13) and adopt an 
“alternatively activated” (M2) phenotype, which suppresses host defenses and facilitates wound 
healing and tissue remodeling to resolve inflammation and restore homeostasis at the inflamed 
site (Galli, Borregaard, and Wynn 2011, Gordon 2003, Sica and Mantovani 2012, Mantovani et al. 
2013). This oversimplified segregation of macrophage phenotypes was originally applied to in 
vitro systems and has been widely used to provide a conceptual framework for subsequent 
research.  However, given the complexity of in vivo microenvironments, macrophages exhibit 
phenotypes across a broad spectrum of activation states, and the simple M1/M2 dichotomy is 
unlikely to reflect physiological macrophage phenotypes (Martinez and Gordon 2014, Mosser and 
Edwards 2008, Xue et al. 2014). 
Macrophages are crucial components in the pathogenesis of many inflammatory 
diseases, including atherosclerosis (Moore and Tabas 2011, Moore, Sheedy, and Fisher 2013, 
Hansson and Hermansson 2011), IBDs (Mowat and Bain 2011, Bain and Mowat 2014a, b), RA 
(Kinne et al. 2000, Maruotti et al. 2007, Kinne, Stuhlmuller, and Burmester 2007, Davignon et al. 
2013) and airway inflammation/asthma (Wynn, Chawla, and Pollard 2013, Careau and 
Bissonnette 2004, Careau et al. 2010, Bang et al. 2011, Balhara and Gounni 2012). Lipid-laden 
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macrophages are typically observed at atherosclerotic plaques. These maladaptive macrophages 
can induce a nonresolving inflammatory response leading to robust accumulation of cells, lipid, 
and matrix at the plaque. Defective macrophage efferocytosis (engulfment of dead cells) and 
enhanced apoptosis contribute to formation of a necrotic plaque core that might eventually 
rupture, causing platelet aggregation and thrombus formation (Moore and Tabas 2011, Moore, 
Sheedy, and Fisher 2013). The functional importance of myeloid cells in atherosclerosis is 
supported by experimental evidence that interventions to alter monocyte recruitment and/or 
survival can markedly affect disease progression (Lessner et al. 2002, Swirski et al. 2006, 
Landsman et al. 2009). Airway inflammation typically accompanies airway allergic asthma, 
another disease involving macrophages. The microenvironment in asthma is dominated by type 
2-associated cytokines (e.g., IL-4 and IL-13), which preferentially polarize macrophages into the 
M2 state (Wynn, Chawla, and Pollard 2013). Elevated numbers of IL-4R+ macrophages have 
been reported in asthmatic patients with defective lung function (Melgert et al. 2011). Moreover, 
the presence of IL-4R+ macrophages exacerbates allergen-induced airway inflammation, whereas 
reduction of IL-4R+ macrophages alleviates this disease (Ford et al. 2012, Moreira et al. 2010).  
Neutrophils, another major component of the innate immune response, are among the 
first cells recruited to inflammatory sites. These cells possess multiple means of eliminating 
invading pathogens, i.e., phagocytosis of microorganisms, degranulation to release antibacterial 
proteins, and emanation of neutrophil extracellular traps (NETs) (Kolaczkowska and Kubes 2013, 
Wright et al. 2010). Recently, many properties of neutrophils favoring the resolution of 
inflammation have been revealed (Jones et al. 2016), including production of Annexin A1 
(Scannell and Maderna 2006) and lipid (e.g., LXA4 and 13-series resolvins) pro-resolution 
mediators (Fierro et al. 2003, Dalli, Chiang, and Serhan 2015), chemokine/cytokine scavenging 
(e.g., CCL3 and CCL5) (Ariel et al. 2006), and apoptosis-induced macrophage efferocytosis 
(Leitch et al. 2008, Hallett et al. 2008). Similarly to macrophages, neutrophils are associated with 
multiple inflammatory syndromes, such as RA (Wipke and Allen 2001, Wright, Moots, and 
Edwards 2014, Wittkowski et al. 2007), chronic obstructive pulmonary disease (Hoenderdos and 
Condliffe 2013, Pesci et al. 1998), and IBDs (Fournier and Parkos 2012, Campbell et al. 2014). In 
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IBDs, for example, neutrophils contribute to elimination of pathogens and immune cell (e.g., 
macrophages) recruitment and activation, as well as mucosal wound healing and resolution of 
inflammation. Of note, precise roles of neutrophils during intestinal inflammation are currently 
under investigation and are highly debated (Campbell and Colgan 2015, Fournier and Parkos 
2012). Some studies using colitis models, either chemically induced (dextran sulfate sodium [DSS] 
or dinitrobenzene sulfonic acid/trinitrobenzene sulfonic acid [DNBS/TNBS]) or immune system 
dysregulation–induced (CD4+CD45RBhi T cell transfer), showed that neutrophil depletion 
exacerbates colitis, suggesting a beneficial role of neutrophils in this setting (Kuhl et al. 2007, 
Zhang et al. 2011); however, other studies showed a completely opposite phenotype in which 
neutrophil depletion ameliorates colitis (Natsui et al. 1997, Kankuri et al. 2001). Additionally, the 
role of neutrophils could also depend on the concomitant presence of monocytes and 
macrophages (Qualls et al. 2006). Therefore, while neutrophils are clearly associated with 
intestinal inflammation, whether they exert beneficial or detrimental effects appears to be model 
dependent and condition dependent.  
HIF IN MYELOID CELLS 
It is noteworthy that myeloid cells localize predominantly within hypoxic subdomains of 
tumors and sites of inflammation, and multiple mechanisms have been proposed to explain how 
hypoxia promotes recruitment and retention of myeloid cells (Murdoch, Giannoudis, and Lewis 
2004).  Both HIF-1α and HIF-2α regulate myeloid migratory activity: HIF-1α is recruited to the 
CXCR4 promoter, stimulating CXCR4 transcription in human monocytes experiencing hypoxia 
(Schioppa et al. 2003). Moreover, CXCR4 is a key chemokine receptor mediating chemotactic 
responses to CXCL12 ligand, which is upregulated in ischemic tissues such as arthritic joints 
(Hitchon et al. 2002). The HIF-1α/PDK1 axis has been recently shown to contribute to 
macrophage migratory activity via induction of active glycolysis (Semba et al. 2016). For HIF-2α, 
Casazza and colleagues demonstrated a semaphorin 3A/neuropilin1–dependent 
(SEMA3A/NRP1-dependent) means of macrophage positioning within the tumor. Here, NRP1 
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repression, which triggers macrophage retention in hypoxic regions, is mediated by HIF-2α–
dependent NF-κB activity (Casazza et al. 2013).  
Given the preferential localization of myeloid cells in hypoxic regions, significant efforts 
have defined how HIF-1α and/or HIF-2α promote myeloid cell adaptation to hypoxic environments 
and mediate inflammation (Figure 1). Cramer and colleagues were the first to demonstrate the 
importance of HIF-1α in macrophage and neutrophil function in the setting of inflammation 
(Cramer et al. 2003). HIF-1α was ablated in myeloid cells using Lysozyme M (LysM) promoter –
driven Cre recombinase, which is specific for the myeloid lineages, i.e., monocytes, macrophages, 
neutrophils, etc. Myeloid-specific Hif1a deletion results in defective glycolysis and ATP generation, 
leading to impairment of myeloid cell motility, invasiveness, aggregation, and bacterial killing. 
Moreover, mice with myeloid-specific HIF-1α deficiency are protected against acute and chronic 
cutaneous inflammation and arthritis. Subsequent studies investigating HIF-1α specifically in 
neutrophils demonstrated that hypoxia-induced inhibition of neutrophil apoptosis is dependent on 
HIF-1α (Walmsley et al. 2005), and that HIF-1α is required for phagocytes to fully exert their 
bactericidal activity (Peyssonnaux et al. 2005). More recent attention has focused on myeloid cell 
immunometabolism (Kelly and O'Neill 2015, O'Neill and Pearce 2016). Myeloid cells can undergo 
metabolic reprogramming to adapt to critical changes in the microenvironment. Tannahill and 
colleagues demonstrated that LPS exposure can alter glutamine-dependent anaplerosis 
(replenishment of TCA cycle intermediates) to elevate succinate levels, which further stabilize 
HIF-1α in macrophages, resulting in increased production of IL-1β (Tannahill et al. 2013). These 
findings serve as an excellent example of how HIF-1α–dependent immunometabolism can 
directly affect cytokine production by macrophages. 
The role of HIF-2α in myeloid cells has also been investigated using the LysM-Cre–
mediated deletion strategy. Macrophages lacking HIF-2α exhibit defects in the production of 
inflammatory cytokines/chemokines in response to hypoxia, migration, and invasion. Myeloid HIF-
2α deficiency also protects mice in models of sepsis, cutaneous inflammation, peritonitis, 
hepatocellular carcinoma, and colitis-associated colorectal cancer (Pesci et al.) (Imtiyaz et al. 
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2010). Like HIF-1α, neutrophil HIF-2α contributes to hypoxia-induced inhibition of apoptosis. HIF-
2α deficiency increases neutrophil apoptosis in vivo and ex vivo, leading to suppression of 
neutrophilic inflammation and inflammatory responses during acute lung injury (Thompson et al. 
2014).  
One interesting observation from the work of Imtiyaz and colleagues (Imtiyaz et al. 2010) 
is that, unlike myeloid HIF-1α, HIF-2α deficiency does not alter cellular ATP production. The 
notion that HIF-1α and HIF-2α exert non-redundant or even opposing functions in macrophages 
is further supported by a study showing that HIF-1α and HIF-2α differentially regulate NO 
production by controlling expression of iNOS and arginase 1, respectively (Takeda et al. 2010). 
Given the complex roles of HIF-1α and HIF-2α in macrophages, pan-HIF inhibition via 
pharmacological or genetic methods (i.e., Arnt deletion) is warranted. In a murine CAC model, 
treatment with the HIF inhibitor acriflavine reduces both tumor burden and macrophage infiltration 
(Shay et al. 2014). Additionally, myeloid cell–specific ARNT deficiency reduces macrophage pro-
inflammatory cytokine production, and mice lacking myeloid ARNT are protected from cutaneous 
inflammation and exhibit delayed wound healing (Scott et al. 2014).  
In the following sections, we will discuss the roles of myeloid HIF-αs in the settings of 
specific inflammatory diseases, as summarized in Table 1. 
Atherosclerosis 
Atherosclerosis is a chronic inflammatory disease of the arterial vasculature. Retention of 
apolipoprotein B–containing lipoproteins and accumulation of cholesterol-laden macrophages in 
the artery wall contribute to this syndrome. Monocytes are first recruited to differentiate into 
mononuclear phagocytes and ingest lipoproteins; however, lipid buildup in these cells transforms 
them into foam cells that exhibit dysregulated lipid metabolism and elevated secretion of pro-
inflammatory cytokines (e.g., IL-6 and TNF-α) and macrophage retention factors (i.e., netrin 1 and 
semaphorin 3E). Foam cells promote the further progression of atherosclerosis (Moore and 
Tabas 2011, Moore, Sheedy, and Fisher 2013).  
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Elevated levels of HIF-1α and HIF-2α are detected in human atherosclerotic carotid 
plaques compared with normal arteries, where HIF-1α colocalizes with CD68, a macrophage 
marker (Pedersen et al. 2013). Hypoxia has been implicated as a pathogenic factor in 
atherosclerosis and contributes to the pro-atherosclerotic functions of macrophages  (Figure 2A) 
(Marsch, Sluimer, and Daemen 2013). Several reports showed that lipid uptake and foam cell 
formation are dependent on hypoxia and HIF-1α (Jiang et al. 2007, Crucet et al. 2013, Parathath 
et al. 2011). Both murine and human macrophage cell lines increase cellular neutral lipid content 
when cultured under hypoxic conditions; however, this effect is reversed upon HIF-1α depletion. 
Multiple HIF-1α–dependent mechanisms have been proposed for this phenotype. For example, 
hypoxia enhances expression of lectin-like oxidized low-density lipoprotein (oxLDL) receptor-1 
(LOX-1), which promotes oxLDL uptake in the murine macrophage cell line RAW264.7; silencing 
of HIF-1α diminishes the upregulation of LOX-1 (Crucet et al. 2013). Hypoxic J774 murine 
macrophages exhibit elevated sterol accumulation due to (a) enhanced sterol synthesis via 
increased 3-hydroxy-3-methyl-glutaryl-CoA (HMG-CoA) reductase activity and (b) suppressed 
cholesterol efflux due to altered subcellular localization of ATP-binding cassette subfamily A 
member 1 (ABCA1) (Parathath et al. 2011). These phenotypic changes are also HIF-1α-
dependent. In U937 human monocytes, oxLDL treatment increases the expression of 70 out of 96 
key genes that are known to be involved in atherosclerosis, while 57 of these genes (e.g., 
cyclooxygenase-2 [COX-2], vascular cell adhesion molecule [VCAM-1], and IL-1β) are 
downregulated with HIF-1α siRNA pretreatment (Jiang et al. 2007). Other pro-atherosclerotic 
functions of macrophages, such as promotion of angiogenesis and proteoglycan synthesis, are 
also dependent on HIF-αs (Hutter et al. 2013, Asplund et al. 2010). In a coculture system of 
human monocytes/macrophages and endothelial cells, oxLDL strongly induces HIF1A and 
VEGFA expression in macrophages, while increasing endothelial cell tube formation. Of note, 
oxLDL pro-angiogenic effects are partially lost upon HIF-1α inhibition (Hutter et al. 2013). The 
notion that myeloid HIF-1α can promote angiogenesis through VEGF upregulation is 
demonstrated in other studies as well (Ahn et al. 2014). Macrophages can also contribute to 
pathogenesis by secreting proteoglycans (PGs) such as versican, which modulate lipoprotein 
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retention and the activity of enzymes, cytokines, and other growth factors in atherosclerotic 
lesions. Increased versican and perlecan expression is detected in macrophages under hypoxia; 
versican is coregulated by HIF-1α and HIF-2α, while perlecan is only dependent on HIF-1α 
(Asplund et al. 2010). Myeloid HIF-1α is also a critical regulator of both glycolytic metabolism and 
pro-inflammatory activation of macrophages, and is stabilized by cues in the atherosclerotic 
microenvironment, such as hypoxia and cytokines. HIF-1α increases transcription of the gene 
encoding 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 (PFKFB3), a key enzyme in the 
glycolytic pathway, leading to (a) increased glycolytic flux, (b) increased pro-inflammatory 
cytokine production (e.g., TNF-α), and (c) maintenance of macrophage viability (Tawakol et al. 
2015). Together, these studies reveal that HIF-αs are crucial components in determining 
macrophage pro-atherosclerotic functions.  
Unfortunately, in vivo studies do not always provide consistent findings. In a wire-induced 
vascular injury model, myeloid HIF-1α promotes vascular inflammation and remodeling 
manifested by increases in TNF-α and IL-6 levels proximal to the injury site and neointimal 
thickening of injured arteries (Nakayama et al. 2013). However, a recent in vivo genetic and drug-
based approach suggested the opposite effect in a different mouse model, indicating that HIF-1α 
and HIF-2α accumulation correlates with reduced atherosclerosis development. The authors 
inhibited PHD2, resulting in HIF-1α and HIF-2α stabilization, by administering a pharmacological 
inhibitor (FG-4497) in an LDL receptor–deficient model of atherosclerosis or by crossing Hif-p4h-2 
hypomorphic (Hif-p4h-2gt/gt) mice with LDL receptor–deficient mice. PHD2 inhibition led to 
reductions in levels of atherosclerotic plaque formation, weight gain, insulin resistance, liver and 
white adipose tissue (WAT) mass, adipocyte size, number of inflammation-associated WAT 
macrophage aggregates, and high-fat diet–induced increases in serum cholesterol levels (Rahtu-
Korpela et al. 2016). The discrepancy with previous findings could be due to non–myeloid-specific 
inhibition of PHD2 in vivo. As such, the in vivo role of myeloid HIF signaling in atherosclerosis 
requires further investigation. 
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Adipose tissue inflammation and obesity 
Adipose tissue hypoxia, chronic inflammation, and macrophage infiltration are key 
characteristics of obesity (Xu et al. 2003, Weisberg et al. 2003, Wellen and Hotamisligil 2005, 
Olefsky and Glass 2010). In lean mice, a majority of the adipose tissue macrophages (ATMs) are 
alternatively activated M2 macrophages, which suppress pro-inflammatory responses and 
maintain adipocyte insulin sensitivity by elevated expression of arginase 1 and IL-10, among 
other factors. In the setting of obesity, the number of macrophages is increased and their 
phenotype altered. Many macrophages are in a classically activated (M1) state, which produces 
NO and secretes pro-inflammatory cytokines, such as IL-1β, TNF-α, and IL-6. These cytokines 
potentiate inflammatory responses in adipose tissue that eventually result in insulin resistance 
(Wellen and Hotamisligil 2005, Odegaard and Chawla 2011, Chawla, Nguyen, and Goh 2011, 
Lumeng, Bodzin, and Saltiel 2007). However, a shift in macrophage polarization in lean versus 
obese humans is debated. Aron-Wisnewsky and colleagues reported a more M1 than M2 
polarization of macrophages (defined by CD40 and CD206 expression, respectively) in obese 
patients, which shifts to a less pro-inflammatory profile after weight loss (Aron-Wisnewsky et al. 
2009). A more recent study, however, demonstrated that even though macrophage numbers 
increase in adipose tissue of obese patients, most of these ATMs are predominantly M2 
macrophages (defined by CD163 and IL-10 expression) (Fjeldborg et al. 2014). These contrasting 
observations may be a consequence of the oversimplified dichotomy of macrophage polarization 
(see above). In the work of Wentworth and colleagues, ATMs were found to be positive for both 
M1 (CD11c) and M2 (CD206) markers, exhibiting a pro-inflammatory status associated with 
insulin resistance in obese humans (Wentworth et al. 2010).  
In obese patients, higher HIF-1α levels are evident in adipose tissue (Cancello et al. 
2005), and hypoxia and HIF signaling regulate ATM functions in the setting of obesity (Figure 2B). 
Fujisaka and colleagues showed that adipose tissue hypoxia induces pro-inflammatory 
phenotypes of M1 ATMs, with elevated expression levels of pro-inflammatory cytokines and 
hypoxia-related genes (Fujisaka et al. 2013). In contrast with HIF-1α’s pro-inflammatory roles in 
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ATMs, macrophage HIF-2α has been suggested to ameliorate adipose tissue inflammation and 
insulin resistance (Choe et al. 2014). Choe and colleagues demonstrated that HIF-2α 
overexpression in macrophages represses NO production and expression of pro-inflammatory 
cytokine genes. On the other hand, silencing HIF-2α in palmitate-treated macrophages increases 
NO production, indicating that HIF-2α is required to downregulate palmitate-induced NO 
production. Macrophage HIF-2α also regulates the crosstalk between macrophages and 
adipocytes. Adipocytes cocultured with wild-type macrophages exhibit decreased insulin signaling, 
while coculture with HIF-2α–deficient macrophages not only reverses the decrease in insulin 
signaling, but also stimulates adipocyte pro-inflammatory responses. In a murine model of high-
fat diet–induced obesity, HIF-2α haplodeficient (Epas1+/–, “Hif2a+/–” herein) mice were more 
susceptible to adipose tissue inflammation and became insulin resistant. Upon macrophage 
depletion, both insulin resistance and adipose tissue inflammation improved in this model (Choe 
et al. 2014). In summary, myeloid HIF-1α promotes adipose tissue inflammation by aiding 
macrophage M1 polarization, while myeloid HIF-2α constrains the inflammatory response and 
insulin resistance in adipose tissue. These conclusions are consistent with the understanding that 
different polarization states of macrophages exert opposite effects on adipose tissue inflammation, 
and are also consistent with the notion that HIF-1α is required for M1 polarization of 
macrophages, and HIF-2α for M2 polarization (Takeda et al. 2010). However, another study 
suggests that hypoxia potentiates palmitate-induced expression of the pro-inflammatory genes IL-
6 and IL-1β independently of HIF-1α and HIF-2α in human macrophages. Instead, their induction 
occurs via activation of JNK and p38 MAPK signaling (Snodgrass et al. 2016). Another group 
proposed that insulin resistance and metabolic dysregulation in obese mice are mainly regulated 
by adipocyte HIF-2α, but not myeloid HIF-2α (Garcia-Martin et al. 2015). Clearly, additional effort 
is needed to determine the extent of HIF-α–mediated regulation of ATM phenotypes and whether 
HIF-α–dependent ATM phenotypic changes are sufficient to alter adipose tissue inflammation 
and obesity. 
 
17 
 
Sepsis 
Sepsis is a life-threatening systemic illness that is normally induced by microbial infection 
and may result in fatal multi-organ failure in patients. Hyperactivation of the innate immune 
system is believed to be a key component of this pathophysiology. Macrophages and neutrophils 
release cytokines, chemokines, and complement-activation mediators soon after the initial 
microbial stimuli (Rittirsch, Flierl, and Ward 2008, Fink and Warren 2014, Zinkernagel, Johnson, 
and Nizet 2007). LPS, a lipoglycan found in the outer membrane of gram-negative bacteria and 
often used to induce murine sepsis or endotoxemia, has been shown to stabilize macrophage 
HIF-1α via p42/44 MAPK and NF-κB signaling pathways (Frede et al. 2006). HIF-1α subsequently 
promotes macrophage in vitro production of pro-inflammatory cytokines such as TNF-α, IL-6, IL-
1β, IL-1α, IL-4, and IL-12. When mice with conditional Hif1a deletion in the myeloid lineage are 
challenged with LPS, they exhibit reduced hypothermia and hypotension, along with enhanced 
survival compared with mice that express myeloid HIF-1α (Peyssonnaux et al. 2007). Myeloid 
HIF-1α deficiency is also protective in a gram-positive endotoxin-induced murine sepsis model 
(Mahabeleshwar et al. 2012).  Similar to HIF-1α, deletion of myeloid HIF-2α is also protective 
against sepsis. Cultured bone marrow–derived macrophages (BMDMs) isolated from mice with 
myeloid HIF-2α deficiency also exhibit decreased pro-inflammatory cytokine and increased 
antiinflammatory cytokine production in response to LPS stimulation. Additionally, myeloid-
specific HIF-2α deficiency promotes survival in LPS-challenged mice (Imtiyaz et al. 2010). 
Collectively, these data show that both HIF-1α and HIF-2α contribute to macrophages’ 
pathogenic roles in septic pathology. This conclusion is further supported by a more recent study 
in which 2-methoxyestradiol (2-ME2), a HIF-1α inhibitor (Mooberry 2003), protected mice from 
both LPS- and cecal ligation and puncture–induced (CLP-induced) sepsis. Suppression of 
cytokines by 2-ME2 was observed in LPS-stimulated peritoneal macrophages, indicating that 
macrophage phenotypic alterations also contributed to the survival phenotype (Yeh et al. 2011) 
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Airway allergy and asthma 
Although airway allergy is a chronic inflammatory disease primarily driven by DCs and 
Th2 T lymphocytes, lung macrophages have also been implicated in airway inflammation and 
asthma (Careau and Bissonnette 2004, Careau et al. 2010, Bang et al. 2011). In a house dust 
mite (HDM) antigen–induced experimental model of airway allergy, myeloid HIF-1α deficiency 
renders mice more susceptible to these stimuli (Toussaint et al. 2013). Toussaint and colleagues 
found that lung macrophage HIF-1α drives expression of immunosuppressive IL-10 to impair DC 
activation and Th responses (Toussaint et al. 2013). A similar protective effect of myeloid HIF-1α 
is also evident in the setting of pulmonary fungal infections. Shepardson and colleagues found 
that mice with myeloid HIF-1α deficiency are more susceptible to pulmonary challenge with 
Aspergillus fumigatus, are defective in fungal clearance, and exhibit decreased lung neutrophil 
numbers. These phenotypes can be partly attributed to decreased production of CXCL1 and 
increased neutrophil apoptosis (Shepardson et al. 2014). Contradictory to the finding that 
macrophage HIF-1α prevents airway allergy, a study by Byrne and colleagues suggests that 
development of airway allergy is dependent on macrophage HIF-1α. They demonstrated that 
HDM increases HIF-1α abundance in the lung, inducing VEGF and CXCL1 production in primary 
lung macrophages in a HIF-1α–dependent manner. Pharmacological HIF-1α inhibition in this 
model suppresses pulmonary allergic inflammation and VEGF and CXCL1 secretion (Byrne et al. 
2013). Using an ovalbumin-induced (OVA-induced) asthma model, others have shown that 
myeloid HIF-1α deficiency reduces airway hyperresponsiveness and eosinophil infiltration. 
Furthermore, HIF-1α and HIF-2α directly regulate eosinophil chemotaxis in opposing ways (Crotty 
Alexander et al. 2013). Therefore, the role of myeloid HIF-1α in airway diseases remains very 
complex, and varies in different experimental models. 
Gastritis 
Inflammation in the gastric mucosa is most commonly induced by Helicobacter pylori 
infection in humans. Chronic gastritis may progress to gastrointestinal ulcers or gastric cancer 
(Fox and Wang 2007). Like other inflammatory diseases, recruitment of immune cells is also 
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evident during gastric inflammation, and macrophage depletion using drug-loaded liposomes has 
been shown to ameliorate the pathology of H. pylori–induced gastritis (Kaparakis et al. 2008). A 
recent report (Matak et al. 2015) specifically examined the role of myeloid HIF-1α in gastritis. The 
authors found that HIF-1α levels are positively correlated with the severity of gastritis in patients 
with H. pylori infections, and HIF-1α is readily observed in macrophages from patient biopsies. In 
vitro, H. pylori preferentially upregulates Hif1a and downregulates Hif2a transcription in BMDMs, 
while expression of pro-inflammatory cytokines is dependent on HIF-1α. Elevated HIF-1α levels 
also contribute to bactericidal activity of both neutrophils and macrophages. Interestingly, in a 
murine model of H. pylori–induced gastritis, mice with myeloid-specific HIF-1α deletion failed to 
exhibit changes in bacterial loads as compared with wild-type animals. Even though myeloid-
specific HIF-1α deficiency blocks the induction of pro-inflammatory gene expression upon H. 
pylori infection, more severe gastritis is observed in these animals, characterized by worsened 
histopathological grading, greater immune cell infiltration, and a higher cellular proliferation index 
compared with infected wild-type animals (Matak et al. 2015). Overall, myeloid HIF-1α appears to 
be protective in H. pylori–mediated gastritis; however, additional work is needed to fully explain 
these counterintuitive phenotypes.  
Renal fibrosis and inflammation 
Macrophages represent the dominant infiltrating cell type during progression of chronic 
kidney disease (CKD), driven partially by low O2 availability in the kidney (Fu, Colgan, and 
Shelley 2016, Erwig 2008, Duffield 2010). Kobayashi and colleagues addressed the role of 
myeloid HIF-αs using the typical LysM-Cre strategy in a murine unilateral ureteral obstruction–
induced (UUO-induced) kidney injury model. Activation of myeloid HIF via LysM-Cre–driven Vhl 
deletion attenuates renal inflammation, while deletion of both myeloid Hif1a and Hif2a enhances 
inflammation, as indicated by increased F4/80+ cell numbers in the kidney. However, the 
presence of myeloid HIF-αs does not alter renal fibrosis. The authors suggest that hypoxia and/or 
myeloid HIF-α activation alleviates renal inflammation via suppression of Ccr2 and Ccl2, which 
are crucial for monocyte recruitment (Kobayashi et al. 2012). The notion that myeloid HIF-1α 
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regulates UUO-induced nephropathy is further supported by another study using the same LysM-
Cre model; however, Tateishi and colleagues reported that myeloid HIF-1α deletion promoted 
renal fibrosis but did not alter macrophage accumulation in the UUO model. They suggested a 
different mechanism for the protective role of myeloid HIF-1α in renal fibrosis: suppression of 
renal connective tissue growth factor (CTGF) within renal cells (Tateishi et al. 2015). The 
discrepancy between the two reports could be due to deletion of two isoforms of HIF-α versus 
deletion of HIF-1α alone. Nevertheless, both studies suggest a protective role for myeloid HIF-αs 
in CKD, which partly supports the observation in patients with CDK that elevated renal HIF-1α 
expression correlates with less severe disease (Hung et al. 2013). 
Cancer-associated inflammation 
A strong link between chronic inflammation and tumor progression has been clearly 
evident for some time. For example, patients with IBDs are at increased risk of developing 
colorectal cancer (Eaden, Abrams, and Mayberry 2001, Jess, Rungoe, and Peyrin-Biroulet 2012, 
Danese and Mantovani 2010). Similar to sites of inflammation, the tumor microenvironment is 
also highly hypoxic. Macrophages predominantly accumulate in hypoxic regions, change their 
gene expression profiles in response to low O2, and function in response to limited O2 availability 
(Murdoch, Giannoudis, and Lewis 2004). Significant effort has delineated the respective roles of 
myeloid HIF-1α and HIF-2α in the tumor setting, beyond the two examples we will summarize 
here. In a PyMT model of breast cancer, loss of myeloid HIF-1α significantly decreases tumor 
mass and inhibits tumor progression, likely through suppression of cytotoxic T cell response to 
the tumors (Doedens et al. 2010). As for HIF-2α, Imtiyaz and colleagues demonstrated that 
myeloid HIF-2α deficiency leads to reduced tumor burden and progression in a murine CAC 
model, while ablating macrophage infiltration of murine hepatocellular carcinoma. The authors 
suggest that these results could partly be due to defective migration and invasion of 
macrophages with HIF-2α loss (Imtiyaz et al. 2010). For a more comprehensive discussion of 
myeloid HIF-αs in cancer, please refer to these reviews (Henze and Mazzone 2016, Triner and 
Shah 2016). 
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SUMMARY 
Overall, hypoxia and inflammation are clearly inextricably linked. Hypoxia can be a strong 
contributory factor in certain inflammatory diseases; in turn, inflammation sites often exhibit low 
O2 tension. Myeloid cells are major components of innate immunity that are tightly associated 
with inflammation in different tissues and found predominantly localized within the hypoxic 
regions of inflamed tissues. Myeloid cell infiltration on its own can contribute to O2 deprivation at 
these sites. In response to hypoxia, myeloid cells stabilize HIF-αs, which facilitates their 
metabolic reprogramming and other adaptations, allowing myeloid cells to take on transient roles 
in different stages of disease progression. In many types of inflammation described in this chapter, 
the roles of myeloid HIF-αs remain incompletely described. In many cases, myeloid HIF-1α and 
HIF-2α have nonredundant or even opposing effects on myeloid cell functions (Keith, Johnson, 
and Simon 2012). Therefore, many questions concerning the role of HIF-αs in myeloid cells 
require further investigation. For example, in specific inflammatory diseases, it is unclear if it 
would be beneficial or detrimental to target HIF-αs. If targeting of HIF-αs is beneficial, then should 
a specific HIF-α isoform or both isoforms be targeted? Even if all mechanisms mediated by HIF in 
inflammatory myeloid cells are elucidated, clinical translation will still be challenging. For example, 
how can HIF be specifically targeted in myeloid cells? How efficient will these therapies be? 
Nevertheless, oxygen-sensing pathways in myeloid cells are clearly key determinants of their 
physiological and pathological functions and these pathways remain attractive therapeutic targets. 
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CHAPTER 2 
Myeloid cell hypoxia-inducible factors promote resolution of inflammation in 
experimental colitis 
This chapter has been adapted from the following manuscript: Lin, N.,Shay, J.E.S., Xie, H., Lee, 
D.S.M., Skuli, N., Tang, Q., Zhou, Z., Azzam, A., Meng, H., Wang, H., FitzGerald, G.A., and 
Simon, M.C. Myeloid cell hypoxia-inducible factors promote resolution of inflammation in 
experimental colitis. Front Immunol (under review). 
 
INTRODUCTION 
Hypoxia (low oxygen tension) is evident in many pathological contexts, including chronic 
intestinal inflammation, commonly known as inflammatory bowel diseases (IBD) (Colgan and 
Taylor 2010, Taylor and Colgan 2007). Healthy colon tissue exhibits O2 partial pressures ranging 
from ~85 mmHg in intestinal crypts to <10 mmHg in villus tips (Zheng, Kelly, and Colgan 2015). 
This “physiological” hypoxia is profoundly exacerbated in the context of active inflammation, as 
revealed in murine models of IBD (Colgan and Taylor 2010, Taylor and Colgan 2007, Karhausen 
et al. 2004) . A well characterized cellular response to O2 deprivation is activation of hypoxia-
inducible factor (HIF) transcriptional regulators, comprised of an O2-sensitive α-subunit (HIF-1α or 
HIF-2α) and a constitutively expressed β subunit (HIF-1β, or aryl hydrocarbon receptor nuclear 
translocator [ARNT]). In the presence of O2, HIF-α is hydroxylated by prolyl hydroxylase domain-
containing proteins (PHDs), and then poly-ubiquitinated by the von Hippel-Lindau (pVHL) tumor 
suppressor E3 ubiquitin ligase complex, leading to its degradation by the 26S proteasome 
(Maxwell et al. 1999, Cockman et al. 2000, Jaakkola et al. 2001). Hypoxic conditions inhibit PHD 
enzymes, allowing HIF-α subunits to accumulate, dimerize with their obligate binding partner 
ARNT, and bind to hypoxia-response elements (HREs) to enhance transcription of hundreds of 
genes whose products mediate cellular adaptation to hypoxia, including glycolysis, angiogenesis, 
and inflammatory responses (Majmundar, Wong, and Simon 2010, Lee and Simon 2015, Lin and 
Simon 2016). As hypoxia is a prominent characteristic of inflamed colon tissue, activation of both 
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HIF-1α and HIF-2α, the two best-characterized HIF-α subunits, is also frequently detected in the 
colon of IBD patients (Giatromanolaki et al. 2003, Xue et al. 2013, Ortiz-Masia et al. 2012). 
Inflamed tissues can become hypoxic due to abnormal vascular function (Hatoum, Binion, 
and Gutterman 2005) and enhanced metabolic activities of bacteria and infiltrating immune cells, 
such as myeloid cells, which include granulocytes (i.e. neutrophils, basophils, eosinophils and 
mast cells) and monocytes that differentiate into macrophages and dendritic cells (Lin and Simon 
2016, Soehnlein and Lindbom 2010). When recruited to sites of inflammation, these cells 
eliminate invading pathogens by driving innate immune responses, e.g. phagocytosis or 
inflammatory cytokine secretion. Macrophages and neutrophils accumulate in the mucosa of IBD 
patients (Rugtveit et al. 1997, Thiesen et al. 2014, Kamada et al. 2008, Bressenot et al. 2015, 
Demir et al. 2015) and play critical roles in modulating and resolving inflammation (Qualls et al. 
2006, Zigmond et al. 2012, Platt et al. 2010, Kuhl et al. 2007, Zhang et al. 2011, Natsui et al. 
1997, Kankuri et al. 2001). Moreover, their preferential localization within hypoxic regions 
suggests a potential role of O2 limitation in dictating myeloid cell inflammatory responses. 
Significant effort has elucidated that HIF-1α and HIF-2α in myeloid cells (Lin and Simon 2016) 
have common (Cramer et al. 2003, Imtiyaz et al. 2010, Walmsley et al. 2005, Thompson et al. 
2014), non-redundant (Cramer et al. 2003, Imtiyaz et al. 2010), and opposing functions (Takeda 
et al. 2010, Keith, Johnson, and Simon 2011), reflecting the complexity of HIF function in these 
cells.  
ARNT depletion represents an attractive approach to study pan-HIF inhibition in multiple 
contexts (Wong et al. 2015, Majmundar et al. 2015, Krock et al. 2015). In a murine model of 
colitis, pharmacological HIF stabilization using PHD inhibitors proved to be protective, partly 
through anti-apoptotic effects on epithelial cells (Robinson et al. 2008, Marks et al. 2015, 
Cummins et al. 2008). Notably, HIF-1α and HIF-2α can oppose each other during intestinal 
inflammation: for example, epithelial cell HIF-1α helps maintain intestinal barrier functions during 
colitis (Karhausen et al. 2004, Furuta et al. 2001, Hirota et al. 2010), whereas HIF-2α worsens 
colitis by promoting tumor necrosis factor alpha (TNFα) production in epithelial cells (Xue et al. 
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2013). HIF functions can also differ drastically depending on cell type. For example, dendritic cell-
specific HIF-1α suppresses intestinal inflammation via activation of regulatory T cells (Fluck et al. 
2016), whereas macrophage-specific HIF-1α has been implicated as pathogenic (Backer et al. 
2017, Kim et al. 2018). However, the role(s) of pan-HIF activation specifically in myeloid cells 
during colitis are yet to be fully investigated.  
In this chapter, we show that myeloid HIF-α/ARNT heterodimers are required for efficient 
resolution of inflammation in a dextran sulfate sodium (DSS)-induced acute colitis murine model, 
and confirm that these effects are due to disruption of HIF-1α and HIF-2α signaling. Lamina 
propria neutrophil and monocyte numbers are elevated in mice with myeloid HIF deficiency during 
the resolution phase of acute colitis. Microarray analysis of colonic macrophages indicates that 
their conversion to a “pro-resolving” profile requires a full complement of HIF activities. We also 
identify serum amyloid As (SAAs) as a likely mechanism through which HIF-deficient 
macrophages contributes to aberrant disease resolution. Our findings are the first to connect HIFs 
to SAAs in colitis, and highlight potential clinical benefits of activating myeloid HIF signaling as a 
way to resolve intestinal inflammation.  
RESULTS 
ARNT depletion in myeloid cells disrupts both HIF-1α and HIF-2α transcriptional activity 
To study HIF function in myeloid cells, we generated LysMCre;Arntfl/fl mice to achieve 
myeloid cell-specific Arnt deletion, whereas LysMCre;Arnt+/+ (henceforth LysMCre) mice were 
used as controls. The LysMCre transgene drives efficient deletion of conditional “floxed” alleles in 
neutrophils and macrophages, which increases as monocytes mature into macrophages (Clausen 
et al. 1999). Highly specific Arnt recombination was confirmed using polymerase chain reaction 
(PCR) assays to detect the deleted (1 lox) Arnt allele in DNA isolated from bone marrow-derived 
macrophages (BMDMs) (lane 3-4), but not tail tissues (lane 7-8), in LysMCre;Arntfl/fl mice (Figure 
3A). ARNT protein abundance was assessed by western blot analysis of lysates from BMDMs 
cultured under either normoxic (21% O2) or hypoxic (0.5% O2) conditions for 24 hours, at which 
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time ARNT protein was significantly depleted in LysMCre;Arntfl/fl BMDMs (Figure 3B). Both HIF-
1α and HIF-2α were stabilized under hypoxia, irrespective of the presence or absence of ARNT 
protein (Figure 3B). While not as dramatic as HIF-1α protein stabilization (>8-fold increase), HIF-
2α exhibited perceptible accumulation (>3-fold increase) under hypoxic conditions (Figure 3B). 
The same cells were examined to test whether ARNT depletion was sufficient to abrogate both 
HIF-1α and HIF-2α transcriptional activity. HIF-1α-specific (Ldha, Pgk1), HIF-2α-specific (Arg1, 
Serpine1), and common target genes of both HIF-α subunits (Adm, Vegfa) displayed increased 
transcription in LysMCre BMDMs challenged with hypoxia; however, this induction was greatly 
diminished in LysMCre;Arntfl/fl BMDMs (Figure 3C-E). Notably, neither phagocytosis nor 
intracellular ATP levels were significantly affected by ARNT loss in BMDMs (Figure 4A-B), and 
age-matched LysMCre and LysMCre;Arntfl/fl mice exhibited comparable body weight and fertility 
(data not shown). Furthermore, no obvious differences were observed in peripheral lymphocyte 
composition of mouse spleen, including B cells, T cells, macrophages, neutrophils, monocytes, 
and dendritic cells (Figure 4C). Overall, these data indicate that ARNT depletion disrupts both 
HIF-1α and HIF-2α transcriptional activity in myeloid cells, offering an excellent opportunity to 
study myeloid pan-HIF inhibition in multiple disease models, including colitis.  
Myeloid deficiency of HIF-α/ARNT heterodimers hinders resolution of DSS-induced acute 
colitis 
To determine the effects of myeloid ARNT deficiency in a model of acute colitis, LysMCre 
and LysMCre;Arntfl/fl animals were administered drinking water containing 3% DSS for 5 days, 
followed by 3 days of regular water. Importantly, mice of both genotypes were housed in the 
same cages to minimize potential confounding influences from differing microbiomes. Mice were 
sacrificed on Day 5 ([+]DSS, Day5) and Day 8([+]DSS, Day8) to compare effects on colitis 
“induction” and “resolution” phases, which are crucial for pathogen elimination and homeostatic 
tissue restoration, respectively (Soehnlein and Lindbom 2010, Prame Kumar, Nicholls, and Wong 
2018). As expected, LysMCre and LysMCre;Arntfl/fl mice imbibing regular drinking water for 8 
days ([-]DSS, Day8) showed no body weight loss, diarrhea, or fecal blood (collectively 
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represented by “Disease Activity Index” [DAI], see Methods for scoring system) over the course of 
this experiment (Figure 5A). In contrast, DSS treatment induced colonic inflammation in both 
LysMCre and LysMCre;Arntfl/fl animals, manifested by decreased body weight, increased DAI, 
and shortened colon length (Figure 5A-B). Body weight loss and DAI on Day 5 were largely 
identical in LysMCre and LysMCre;Arntfl/fl mice. Interestingly, as body weight and DAI gradually 
improved in LysMCre mice starting at Day 6, LysMCre;Arntfl/fl mice continued to exhibit weight 
loss and an elevated DAI through Day 8 (Figure 5A). Similarly, Day 5 colon lengths were 
comparable between the two groups; however, LysMCre;Arntfl/fl mice displayed significantly 
shorter colons compared to LysMCre mice on Day 8 (Figure 5B).  
Histological evaluation revealed immune cell infiltration and disrupted epithelium on Day 
5 in both cohorts (Figure 5C). On Day 8, LysMCre mice displayed a colonic histology similar to 
untreated colons, whereas colons from LysMCre;Arntfl/fl mice had elevated immune cell filtration 
and relatively few normal crypt structures (Figure 5C). This difference in histology on Day 8 was 
confirmed and quantified by histopathological scoring (see Methods) (Figure 5D). RNA 
expression and secretion of key pro-inflammatory cytokines (IL1β, IL6, IL12α, and TNFα) were 
also substantially increased in the colon of LysMCre;Arntfl/fl mice, compared to controls, especially 
on Day 8 (Figure 6A-B). Further unbiased cytokine array analysis revealed a more pro-
inflammatory microenvironment in LysMCre;Arntfl/fl colons (Figure 6C-D). Collectively, these data 
suggest that myeloid ARNT is required for proper resolution of acute colitis.  
Loss of either HIF-1α or HIF-2α in myeloid cells phenocopies LysMCre;Arntfl/fl mice in DSS-
induced colitis model 
It is well established that ARNT can heterodimerize with the bHLH/PAS transcription 
factor aryl hydrocarbon receptor (AhR), which also regulates immune responses during intestinal 
inflammation (Mulero-Navarro and Fernandez-Salguero 2016, Lamas, Natividad, and Sokol 2018). 
As expected, increased expression of two AhR target genes was observed in LysMCre BMDMs 
exposed to the AhR agonist (6-formylindolo[3,2-b]carbazole, aka FICZ), but not in 
LysMCre;Arntfl/fl BMDMs (Figure 7A). However, ARNT loss had no effect on AhR target gene   
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expression under hypoxic conditions (Figure 7B), suggesting that AhR contributes little to ARNT-
dependent responses in hypoxic inflamed colon tissue. Moreover, RNA expression assessment 
of sorted colonic macrophages failed to reveal changes in AhR target gene expression between 
the two cohorts (see Figure 13). 
To determine whether myeloid HIF-1α and HIF-2α both contribute to the resolution phase 
of intestinal inflammation, we induced acute colitis in LysMCre;Hif1αfl/fl and LysMCre;Hif2αfl/fl mice 
using an identical treatment regimen as that described above (Figure 5). As before, control 
LysMCre mice regained normal body weight after removal of DSS water, whereas 
LysMCre;Hif1αfl/fl and LysMCre;Hif2αfl/fl animals did not (Figure 8A and 8F). DAI also remained 
high following DSS treatment in these mice, compared to LysMCre controls (Figure 8B and 8G). 
Colon length showed considerable shortening in both HIF-deficient cohorts on Day 8, although 
the difference between LysMCre and LysMCre;Hif2αfl/fl mice failed to reach statistical significance 
(Figure 8C and 8H). Elevated gene expression of key pro-inflammatory cytokines (Figure 8D 
and 8I) and exacerbated histopathology on Day 8 (Figure 8E and 8J) in LysMCre;Hif1αfl/fl and 
LysMCre;Hif2αfl/fl mice further confirmed unresolved inflammation in mice with myeloid HIF-α 
depletion. We conclude that expression of both HIF-1α and HIF-2α in myeloid cells is critical for 
resolving acute colonic inflammation. Interestingly, the hypoxic induction of HIF-2α (see Figure 3) 
and impact of HIF-2α on colitis are less dramatic than HIF-1α (see below for further discussion).  
Myeloid HIF deficiency leads to more neutrophils and monocytes in the inflamed colons 
Elevated and persistent immune responses frequently contribute to IBD pathogenesis. To 
monitor changes in colonic immune cell populations in the context of myeloid HIF disruption, we 
performed a comprehensive FACS analysis of immune cells recovered from the lamina propria of 
LysMCre and LysMCre;Arntfl/fl mice treated with DSS. Compared to control LysMCre mice, 
increased numbers of neutrophils (CD45+, CD11c-, CD11b+, Ly6G+) and monocytes (CD45+, 
CD11c-, CD11b+, Ly6Chi, Ly6G-) (Figure 9A) were observed in LysMCre;Arntfl/fl mice on Day 8, 
expressed either as a percentage of CD45+ cells (Figure 9B) or as the number of cells per mg of 
colon tissue (Figure 9C). DSS treatment elevated neutrophil and monocyte numbers (Figure 9B)  
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in both LysMCre and LysMCre;Arntfl/fl mice on Day 5; however, no significant difference between 
genotypes was detected. We hypothesized that increased numbers of neutrophils and monocytes 
in colonic tissue of LysMCre;Arntfl/fl mice could contribute to more severe inflammation, 
particularly during the resolution phase of acute colitis.  
Interestingly, the percentage of macrophages (CD45+, CD11b+, F4/80+) (Figure 9D) in 
CD45+ cells was significantly higher in LysMCre;Arntfl/fl mice than in LysMCre mice at Day 5 
(Figure 9E). However, by Day 8, the percentage of macrophages between the two groups was 
comparable, suggesting that HIF deficiency in macrophages could be of particular importance for 
the shift from the induction phase to the resolution phase of colitis. As expected, both B and T 
cells showed no significant differences in the lamina propria of LysMCre and LysMCre;Arntfl/fl mice 
(Figure 10), consistent with previous data indicating that the DSS-induced colitis model is 
primarily driven by innate immune cells (Kiesler, Fuss, and Strober 2015). 
Myeloid HIF deficiency contributes to increased neutrophil numbers primarily through 
elevated infiltration 
Neutrophils often exert pro-inflammatory functions at sites of inflammation (Kolaczkowska 
and Kubes 2013, Wright et al. 2010), and a neutrophil-derived protein, myeloperoxidase, is widely 
used as a marker of colitis severity in IBD (Kim et al. 2012, Garrity-Park et al. 2012, Hansberry et 
al. 2017). Therefore, we investigated the cellular mechanisms contributing to elevated numbers of 
neutrophils in DSS-treated LysMCre;Arntfl/fl mice. Given that both neutrophils and macrophages 
are targeted by LysMCre recombination strategies, we first enriched neutrophils from bone 
marrow (Figure 11A-B) and compared the efficiency of Arnt deletion in these two cell types by 
PCR (Figure 11C). Neutrophils exhibited relatively lower deletion efficiency (>60%) compared to 
macrophages (>80%) (Figure 11D), which correlated to decreases in Arnt mRNA levels (Figure 
11E). Nevertheless, Arnt deletion in neutrophils was sufficient to disable hypoxic induction of 
Vegfa gene expression in LysMCre;Arntfl/fl BMDNs (Figure 11F). We next determined if 
neutrophils were affected by cell-intrinsic factors, cell-extrinsic factors, or a combination of the two. 
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Timely neutrophil apoptosis is a key event that initiates the resolution of acute 
inflammation (Soehnlein and Lindbom 2010, Ortega-Gomez, Perretti, and Soehnlein 2013). It was 
therefore plausible that the increase in neutrophil numbers during the resolution phase was due 
to delayed apoptosis; however, given previously described pro-survival functions of both HIF-1α 
and HIF-2α in neutrophils (Thompson et al. 2014, Walmsley et al. 2005), this seemed unlikely. 
Consistent with these observations, untreated LysMCre;Arntfl/fl mice exhibited decreased 
neutrophil viability (Figure 12A). Furthermore, the percentage of dead neutrophils in colon tissue 
from LysMCre and LysMCre;Arntfl/fl mice was indistinguishable at Day 5 and Day 8 (Figure 12A). 
In vitro, the percentage of viable BMDNs after 24-hour culture under normoxia or hypoxia were 
also comparable between LysMCre and LysMCre;Arntfl/fl cohorts (Figure 12B). Caspase 3/7 
activity assessment further supported the notion that ARNT deficiency can promote, as opposed 
to delay, neutrophil apoptosis under hypoxia (Figure 12C), consistent with previous findings 
(Thompson et al. 2014, Walmsley et al. 2005).  
Another critical step in resolving inflammation is the prevention of further neutrophil 
recruitment (Soehnlein and Lindbom 2010, Ortega-Gomez, Perretti, and Soehnlein 2013). We 
therefore tested whether myeloid HIF deficiency enhanced neutrophil infiltration by altering either 
the microenvironment or neutrophil chemotaxis. CXCL1 has long been recognized as a major 
neutrophil chemoattractant, and CXCL1 secretion in the supernatant of colonic explants was 
increased by almost three-fold in LysMCre;Arntfl/fl mice on Day 8, compared to LysMCre mice 
(Figure 12D). In contrast, the levels of CXCR2, the CXCL1 receptor expressed by neutrophils 
(Kolaczkowska and Kubes 2013), were not affected by ARNT status (Figure 12E), suggesting 
that the increased number of neutrophils may reflect the elevated secretion of chemoattractant in 
the gut, rather than enhanced neutrophil migratory ability. Given that CXCL1 production by 
macrophages has been shown to promote neutrophil infiltration in a peritonitis model (De Filippo 
et al. 2013), we next asked if HIF deficiency promoted CXCL1 production by macrophages. 
Expression of Cxcl1 was indeed higher in macrophages sorted from the lamina propria of 
LysMCre;Arntfl/fl mice, suggesting that macrophages could be a major source of CXCL1 in the 
intestine (Figure 12F).  
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HIF-deficient colonic macrophages have a diminished pro-resolving profile 
To overcome inflammation, macrophages must activate “pro-resolving” functions to 
ensure reconstitution of tissue homeostasis (Soehnlein and Lindbom 2010, Ortega-Gomez, 
Perretti, and Soehnlein 2013). To elucidate the exact contribution of HIF-deficient macrophages 
to unresolved colitis, we sorted these cells in colitic tissues from LysMCre (n=5) and 
LysMCre;Arntfl/fl  (n=4) mice on Day 8, and conducted RNA microarray analysis. Unsupervised 
clustering clearly distinguished the two cohorts, indicating similar gene expression patterns 
among mice with the same genotype (Figure 13A). Together, 115 upregulated and 138 
downregulated genes were identified in LysMCre;Arntfl/fl compared to LysMCre macrophages, 
based on a minimum 1.5X absolute change cutoff and a false discovery rate (FDR) adjusted p-
value (stated as q-value here) of 0.05 (Figure 13B, yellow dots). Decreased Arnt gene 
expression was also verified (Figure 13B, black dot). Expression of multiple genes previously 
associated with adverse effects in IBD, including Lcn2, Il1f9, Lrg1, and Mmp9 (Figure 13B, blue 
dots), was higher in LysMCre;Arntfl/fl macrophages. Simultaneously, several genes whose 
products act to limit or resolve colitis (e.g. Areg and Fgl2 [Figure 13B, blue dots]) showed lower 
expression levels in HIF-deficient macrophages. We compared our microarray results with a 
previous genome profiling study performed over the time course of DSS-induced colitis (Fang et 
al. 2011). Twenty-eight genes exhibited overlap between both datasets (see Figure 16B), which 
included Lcn2 and Lrg1, pro-inflammatory genes previously implicated in colitis. Of note, 
expression of two key target genes of AhR signaling (Cyp1a1 and Ugt1a1) was not significantly 
altered in ARNT-deficient intestinal macrophages (Figure 13B, purple dots), further supporting 
the notion that AhR signaling is not a significant contributing factor to the phenotypes we 
observed.  
Given the defective resolution of colitis observed in LysMCre;Arntfl/fl mice, we next asked 
whether conversion to a pro-resolving phenotype was impaired in HIF-deficient macrophages. 
Transcriptomic profile of inflammatory macrophages and resolution phase macrophages has 
been described in a previous study (Stables et al. 2011). By comparing differentially expressed 
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genes in LysMCre;Arntfl/fl and LysMCre macrophages to the published differentially expressed 
genes in inflammatory- and resolution-phase macrophages, we observed that approximately 70% 
of the genes in our list were consistent with a reduction in a pro-resolving phenotype of 
macrophages in LysMCre;Arntfl/fl mice. For example, of the 20 most highly upregulated genes in 
resolution macrophages, 13 (65%) were instead downregulated in sorted LysMCre;Arntfl/fl 
macrophages (Figure 13C, left panel). Similarly, 13 (65%) of the 20 most downregulated genes 
in resolution macrophages were instead upregulated in sorted LysMCre;Arntfl/fl macrophages 
(Figure 13C, right panel). Collectively, these data suggest a critical role of HIF signaling for the 
functional conversion of macrophages, which might underlie the successful shift from induction 
phase to resolution phase in acute colitis. 
Multiple studies suggest that macrophage “polarization” into M1 or M2 fates can regulate 
a variety of inflammatory conditions (Huo et al. 2004, Handberg et al. 2008, Khallou-Laschet et al. 
2010, Nguyen et al. 2011, Kosteli et al. 2010, Moreira et al. 2010, Naura et al. 2010). To test if 
macrophage polarization was affected by Arnt deletion, we cultured LysMCre and LysMCre;Arntfl/fl 
BMDMs under either normoxia or hypoxia, with or without cytokines that induce an M1 (5 ng/mL 
LPS+1 ng/mL IFNγ) or M2 (5 ng/mL IL-4+5 ng/mL IL13) phenotype. Based on qPCR analysis of 
several canonical M1- and M2-associated markers, we found that M1 polarization was enhanced 
(Figure 14A), whereas M2 polarization was suppressed (Figure 14B). In contrast, when 
microarray data of sorted macrophages recovered from colon tissue were subject to a 
comprehensive analysis of M1 and M2 markers, we observed a mixed profile of polarization, 
marked by repression of both M1 and M2 gene signatures (Figure 15). Consequently, it remains 
unclear from these data whether myeloid HIF deficiency favors one polarization state over the 
other in vivo.  
Myeloid HIF deficiency increases serum amyloid A levels in the colon 
Among the differentially regulated genes displayed in Figure 13B, those encoding three 
members of serum amyloid A (SAA) family were identified among the most upregulated genes in 
LysMCre;Arntfl/fl macrophages (red dots). Ingenuity Pathway Analysis (IPA) also identified acute 
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phase response signaling as one of the most activated signaling pathways in LysMCre;Arntfl/fl 
macrophages, which includes Saa1 and Saa3 (Figure 16A). Comparison of our microarray 
results with the temporal genome profiling study of colitis (Fang et al. 2011) revealed Saa3 as 
one of the 6 common genes differentially expressed throughout the time course of disease 
(Figure 16B), implicating a potential role for Saa3 in this disease model. SAA is an acute phase 
response protein whose elevated production is often observed in Crohn’s disease and other 
inflammatory conditions (Niederau et al. 1997, de Villiers et al. 2000, Ye and Sun 2015, Huang 
and Littman 2015). Moreover, SAA has been implicated in mediating defective resolution by 
competing with lipoxin A4, a key pro-resolving molecule, for binding to their common receptor, 
formyl peptide receptor 2 (FPR2) (Bozinovski et al. 2012, El Kebir et al. 2007). Upregulation of 
these genes were first confirmed using qRT-PCR (Figure 16C). Moreover, supernatants from 
colonic explants from LysMCre;Arntfl/fl mice, contained higher levels of SAA1/2 and SAA3 proteins, 
particularly on Day 8, compared to controls (Figure 17A). Expression of two key SAA receptors 
(Fpr2 and Scarb1) was also elevated in the colon tissue of LysMCre;Arntfl/fl mice (Figure 17C), 
reinforcing a potential role for SAA in colitis. We also assessed Saa gene expression in colon 
tissue and found that the trend of Saa expression correlated with disease progression (Figure 
17B). After 5-day DSS treatment, both LysMCre and LysMCre;Arntfl/fl mice exhibited increased 
Saa expression compared to untreated mice. On Day 8, Saa gene expression in LysMCre mice 
declined to a level similar to untreated mice; however, LysMCre;Arntfl/fl mice maintained a high 
level of Saa gene expression, and an elevated level of Saa3. These results again implicate SAA 
in the regulation of colitis resolution.  
KEGG pathway analysis of significantly upregulated genes in LysMCre;Arntfl/fl lamina 
propria macrophages suggested changes in arachidonic acid metabolism (Figure 18A), 
especially increased Ptges1, Cyp2e1 and Ggt1 expression (Figure 18B). Ptges1 encodes 
prostaglandin E synthase 1 (PTGES1), which catalyzes the production of prostaglandin E2 
(PGE2) (Nakanishi and Rosenberg 2013). Since PGE2 elicits diverse functions during 
inflammation, we primarily assessed PGE2 production and key enzymes responsible for it. Ptges1 
and Ptges2 upregulation were confirmed using RT-qPCR (Figure 18C). Interestingly,  
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LysMCre;Arntfl/fl mice exhibited lower levels of PGE2 as compared with LysMCre mice in the gut 
(Figure 18D). Further measurement of PGE2 in BMDM culture supernatants suggested that 
decreased PGE2 production by HIF-deficient macrophages may partially contribute to these 
observations in the colon (Figure 18E, left). Of note, PGE2 generation in BMDNs was 
independent of HIF-α/ARNT heterodimers (Figure 18E, right). Decreased Ptgs2 expression 
(Figure 18C), encoding cyclooxygenase 2 (COX2), in LysMCre;Arntfl/fl lamina propria 
macrophages may be responsible for lower PGE2 levels, despite Ptges1 and Ptges2 upregulation 
which are downstream of COX2 in PGE2 production. Given PGE2 has been shown to facilitate 
resolution of colonic inflammation (Zhang et al. 2015, Grainger et al. 2013, Montrose et al. 2015), 
lower levels of PGE2 may partially contribute to defective resolution in LysMCre;Arntfl/fl mice. 
However, we note differences of colonic PGE2 levels between LysMCre and LysMCre;Arntfl/fl mice 
are modest, suggesting other factors are important as well. 
DISCUSSION 
In the present chapter, we demonstrate that HIF signaling in myeloid cells is essential for 
resolution of acute colitis (Figure 19). Myeloid HIF deficiency increases the infiltration of pro-
inflammatory neutrophils and monocytes, impedes the functional conversion of macrophages to a 
pro-resolving phenotype, and promotes SAA production in the colon during the resolution phase. 
Collectively, these disruptions contribute to defective resolution of colitis in mice with myeloid HIF 
deficiency. 
Previously, pharmacological approaches to stabilize HIFα proteins using PHD inhibitors 
were shown to suppress intestinal inflammation (Marks et al. 2015, Robinson et al. 2008). In line 
with these findings, our study demonstrates that myeloid HIF function is necessary for proper and 
timely resolution of acute colitis, highlighting myeloid cells as active contributors to the anti-
inflammatory effects of PHD inhibitors. In contrast, a previous study shows that depletion of 
myeloid ARNT dampens cutaneous inflammation (Scott et al. 2014). The apparent discrepancy 
between that study and ours is likely explained by the differences in disease models. Given the  
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plasticity of macrophages, it is not surprising for myeloid HIF to elicit different functions in 
response to distinct microenvironments in various types of inflammation. For example, we found 
that myeloid ARNT is dispensable for animal survival in a LPS-induced endotoxemia model and 
macrophage recruitment in thioglycollate (TG) -induced peritoneal inflammation (see Chapter 3). 
These results strongly suggest that potential pharmacological approaches to stabilize HIF should 
be selected carefully to match the cellular hypoxic responses in specific diseases.  
The importance of HIF signaling in distinct cell types, including epithelial cells (Karhausen 
et al. 2004, Furuta et al. 2001, Hirota et al. 2010, Xue et al. 2013), dendritic cells (Fluck et al. 
2016) and T cells (Higashiyama et al. 2012), has been studied in the context of intestinal 
inflammation. We add to these findings by demonstrating that myeloid HIF-1α and HIF-2α are 
crucial to resolve acute colitis. Although myeloid HIF-1α has been recently implicated in 
promoting DSS-induced colitis (Backer et al. 2017, Kim et al. 2018), we hypothesize that these 
disparate results are likely due to different phases of inflammation under examination, and/or 
different effects of the gene promoters driving Cre-mediated recombination. Specifically, Bäcker 
and colleagues (Backer et al. 2017) examined mice up to Day 6 of DSS treatment without time for 
recovery, as opposed to our study where the principal phenotype was captured after removal of 
DSS H2O. Moreover, we utilized LysMCre which targets mature macrophages and Gr-1+ myeloid 
cells, while Kim and colleagues (Kim et al. 2018) chose hMRP8Cre for recombination primarily in 
Gr-1+ granulocytes. These reports underscore the complexity of colitis, and roles of different 
myeloid populations. Moreover, we note the less impressive contribution of HIF-2α, compared 
with HIF-1α, to colitis resolution (Figure 8), which may be due to its less dramatic induction under 
hypoxia in macrophages (Figure 3). We conclude that HIF-1α is the major isoform driving proper 
resolution of intestinal inflammation, with HIF-2α contributing to a lesser extent.  
Previous studies have described a protective role for AhR, another established ARNT 
binding partner, in colitis (Lamas et al. 2016, Wang et al. 2018, Furumatsu et al. 2011). However, 
AhR was globally deleted in these mice. Our findings suggest that myeloid AhR is not likely a 
major contributor to colitis resolution, as disruption of HIF-1α and HIF-2α signaling accounts for 
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the majority of ARNT-dependent effects in our model. Microarray analysis of sorted lamina 
propria macrophages supports our contention that myeloid AhR signaling is not a significant 
factor in this intestinal inflammation model. Furthermore, Chinen and colleagues (Chinen et al. 
2015) reported that myeloid AhR is dispensable for inflammatory response in DSS-induced colitis 
by utilizing the same LysMCre strategy.  
Temporally ordered apoptosis and clearance of neutrophils signals the initiation of 
inflammation resolution (Soehnlein and Lindbom 2010, Ortega-Gomez, Perretti, and Soehnlein 
2013), and we observed that unresolved colitis in LysMCre;Arntfl/fl mice was associated with 
elevated numbers of neutrophils in the lamina propria (Figure 9), correlating with enhanced 
expression of chemotactic signals, as opposed to increased neutrophil lifespan (Figure 12). 
Based on previous understanding that either HIF-1α or HIF-2α prevents neutrophil apoptosis 
under hypoxia (Walmsley et al. 2005, Thompson et al. 2014), we anticipated that neutrophil 
viability would be impaired upon Arnt deletion; however, this was not observed. We speculate that 
increased SAA expression in the colonic microenvironment counterbalances the effects of ARNT 
loss on neutrophil viability, given that SAA has been shown to inhibit neutrophil apoptosis 
(Christenson et al. 2008, El Kebir, Jozsef, and Filep 2008).  
A “partnership” between neutrophils and macrophages is common during inflammation 
(Prame Kumar, Nicholls, and Wong 2018), particularly in its resolution phase (Soehnlein and 
Lindbom 2010). Here, we suggest that HIF-deficient macrophages promote neutrophil chemotaxis 
via elevated CXCL1 secretion. As such, we speculate that HIF signaling plays a more dominant 
role in macrophage functions compared to neutrophils in this setting. In line with this, production 
of PGE2, together with other eicosanoid metabolites (e.g. prostaglandin F2α and thromboxane 
B2) (data now shown), is dependent on HIF signaling in macrophages, but not in neutrophils. 
However, we cannot exclude the possibility that other neutrophil-intrinsic properties are altered 
upon the ARNT loss. This will be investigated in future studies. 
Macrophages adopt a pro-resolving phenotype to facilitate recovery from inflammation 
(Soehnlein and Lindbom 2010, Ortega-Gomez, Perretti, and Soehnlein 2013). Detailed molecular 
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mechanisms underlying this functional macrophage conversion have yet to be elucidated. Here, 
we uncover a requirement for intact HIF signaling for macrophages to adopt a pro-resolving 
phenotype in inflamed colons. Similar to a previous report that resolution phase macrophages 
display neither canonical M1 nor M2 markers (Stables et al. 2011), our study reveals that 
disruption of macrophage HIF signaling impedes conversion to a pro-resolving phenotype, 
without promoting either M1 or M2 identities in vivo. This could be due to the highly complex and 
dynamic microenvironment of colitis. Our findings are consistent with previous studies 
demonstrating that M1 and M2 polarization is more readily conferred in cell culture settings, which 
do not necessarily reflect in vivo conditions (Martinez and Gordon 2014).  
Microarray analysis of colonic macrophages revealed a link between HIF signaling and 
Saa expression in macrophages. An initial attempt to rescue abnormal resolution in 
LysMCre;Arntfl/fl mice by injecting anti-SAA neutralizing antibodies (Li et al. 2015) was 
unsuccessful due to technical complications (data not shown). Given the dearth of validated, 
commercially available neutralizing antibodies for murine SAA, subsequent work will focus on 
generating a genetic deletion of Saa1/2/3 in myeloid cells; however this is beyond the scope of 
the current study. Furthermore, although SAA function has been implicated previously in 
regulating inflammation, other genes upregulated in both colitic tissue and LysMCre;Arntfl/fl 
macrophages, including Stfa3, Asprv1, Wfdc21, and Chil1 (Figure 13B), may also contribute 
important functions.  
In conclusion, we identify myeloid cells as essential contributors to the protective effects 
of HIF activation during colitis, and describe an important role for myeloid HIF signaling in the 
efficient resolution of intestinal inflammation. Myeloid cells present as an attractive target cell 
population for approaches to engage HIF signaling, such as using PHD inhibitors, as a way to 
more effectively bring IBD under control.  
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CHAPTER 3 
Differential roles of myeloid cell HIFs in other inflammatory diseases 
INTRODUCTION 
In addition to acute colitis, both hypoxia and myeloid cells have been implicated in 
playing critical roles in many other inflammatory diseases; for example, colitis-associated 
colorectal cancer (CAC). Macrophages can be “re-educated” by the tumor microenvironment to 
facilitate tumor initiation and malignant progression as tumor-associated macrophages (TAMs) in 
multiple cancer types (Noy and Pollard 2014). Our lab has previously reported that loss of 
myeloid HIF-2α resulted in reduced tumor burden and disease progression in a murine CAC 
model, coincident with decreased TAM infiltration (Imtiyaz et al. 2010). Along the same line, 
inhibition of HIF-α:ARNT dimerization by acriflavine (ACF) limited tumor progression and 
macrophage infiltration in the same CAC model (Shay et al. 2014). Since ACF treatment can also 
hinder HIF signaling in other cells found in the colon, it is difficult to tease out the myeloid-specific 
contribution of HIF inhibition. Therefore, we decided to carefully delineate individual and pan-HIF 
roles that are specific to myeloid cells in this CAC model using conditional deletion of either Hif1α, 
Hif2α, or both by LysMCre.   
A previous study by Imtiyaz and colleagues demonstrated that HIF-2α is required for 
murine skin inflammation, peritonitis, and sepsis (Imtiyaz et al. 2010). This finding was consistent 
with other reports focusing on the role of HIF-1α in skin inflammation and sepsis. Cramer et al. 
reported that conditional HIF-1α depletion in myeloid cells abrogated 12-O-tetradecanoylphorbol-
13-acetate (TPA)-induced ear edema and leukocyte infiltration, exhibiting a similarly 
compromised immune response as in mice with myeloid HIF-2α deficiency (Cramer et al. 2003). 
Likewise, in several sepsis models, myeloid HIF-1α deficiency was demonstrated to reduce 
hypothermia and hypotension, and significantly extended animal survival (Peyssonnaux et al. 
2007, Mahabeleshwar et al. 2012).  Based on these data, I hypothesized that pan-HIF deficiency 
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in myeloid cells would also impair inflammatory responses and alleviate disease symptoms in 
these acute inflammation models.  
In this chapter, I will summarize and discuss the observations made in one cancer and 
three acute inflammation models utilizing mice with individual HIF-α or pan-HIF loss in myeloid 
cells.  
RESULTS 
Loss of both HIF-α subunits worsens tumor burden and progression of murine colitis-
associated colorectal cancer 
To examine the individual and combined roles of myeloid HIF-1α and HIF-2α in 
inflammation-associated cancer, an azoxymethane (AOM)/DSS induced colitis-associated cancer 
(CAC) model was applied to 8-week old mice from the following four colonies: LysMCre, 
LysMCre;Hif1αfl/fl, LysMCre;Hif2αfl/fl, and LysMCre;Hif1αfl/f;Hif2αfl/fl. As shown in Figure 20A, these 
animals were injected with 12.5 mg/kg AOM, a potent carcinogen, on Day 0, followed by three 
cycles of DSS treatment with two-week intervals of regular drinking water in between cycles. This 
experiment was designed to end on Day 98 (14 weeks) to assess tumor formation and colonic 
inflammation. All mice that survived until Day 98 developed polyps along the colon, with the 
majority located towards the distal end and rectum (Figure 20B). Compared with LysMCre 
controls, LysMCre;Hif1αfl/fl and  LysMCre;Hif2αfl/fl mice exhibited slightly more polyps; however, 
LysMCre;Hif1αfl/f;Hif2αfl/fl mice developed the most polyps per mouse (Figure 20C). Using the 
sum of polyp diameter as a measure of tumor burden, LysMCre;Hif1αfl/f;Hif2αfl/fl mice also had a 
significantly greater tumor burden (Figure 20C). Of note, female animals generally suffered less 
tumor burden compared with male animals, especially within the LysMCre;Hif1αfl/f;Hif2αfl/fl cohort 
(Figure 20D). On a per lesion basis, the average size of each polyp, indicated by its diameter, 
was again larger in LysMCre;Hif1αfl/f;Hif2αfl/fl mice compared to LysMCre mice (Figure 21A). 
Unsurprisingly, LysMCre;Hif1αfl/f;Hif2αfl/fl mice also had a higher percentage of larger polyps 
(Figure 21B). Histopathological evaluation of colonic sections from all four cohorts revealed more  
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advanced lesions in LysMCre;Hif1αfl/fl and LysMCre;Hif1αfl/f;Hif2αfl/fl mice (Figure 21C), given that 
adenocarcinoma was only detected in these two cohorts. These results suggest that only the 
absence of both HIF-1α and HIF-2α promotes tumor burden and progression in murine CAC.  
Given the important influence of TAMs on CAC, we further assessed macrophage 
infiltration in LysMCre and LysMCre;Hif1αfl/f;Hif2αfl/fl colonic sections by F4/80 
immunohistochemistry. Accumulation of these cells was observed in both the stalk of each tumor 
and within tumors (Figure 22A). Stalk is the lamina propria area that is above the submucosa. 
Regardless of the large difference in tumor burden, no significant variance of macrophage 
infiltration was observed between LysMCre and LysMCre;Hif1αfl/f;Hif2αfl/fl cohorts (Figure 22B).  
Mice with myeloid HIF-2α deficiency exhibit more severe inflammation and a survival 
disadvantage in the murine CAC model 
One interesting observation made during this AOM/DSS induced CAC experiment was 
that LysMCre;Hif2αfl/fl mice exhibited a survival disadvantage compared with other cohorts, with 
the majority (80%) of the mice dropping off the study during the three cycles of DSS stimulation 
(Figure 23A). Therefore, we suspected that mice with myeloid HIF-2α deficiency may be more 
susceptible to chronic intestinal inflammation. Indeed, the decrease in body weight upon each 
DSS treatment cycle (Figure 23B) and shrinkage of colon length (Figure 23C) at the end of the 
experiment were most drastic in the LysMCre;Hif2αfl/fl cohort, indicating much worse inflammation 
throughout the experimental time course. Consistently, pathohistological grading of inflammation 
severity also suggested a higher percentage of LysMCre;Hif2αfl/fl mice exhibited more severe 
inflammation (Figure 23D). These observations prompted us to examine whether loss of myeloid 
HIF-2α indeed renders mice more susceptible to chronic inflammatory stress. 
Myeloid HIF-2a is not required for DSS-induced chronic colitis pathology 
To determine whether deficiency of myeloid HIF-2α indeed worsens chronic inflammation 
in the gut, LysMCre and LysMCre;Hif2αfl/fl mice were administered three cycles of 2% DSS for 
five days followed by regular drinking water for another five days after each DSS treatment. 
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Similar to the DSS-induced acute colitis model, body weight change, Disease Activity Index (DAI), 
and colon length at the end of the experiment were used as parameters to determine disease 
severity. Neither body weight change nor DAI differed significantly between LysMCre and 
LysMCre;Hif2αfl/fl mice over the experimental course (Figure 24A-B). It is worth noting that 
fluctuations in DAI correlated very well with treatment regimen, in the way that each DSS cycle 
increased DAI and was then reduced by regular drinking water (Figure 24B). Of note, during the 
first cycle, LysMCre;Hif2αfl/fl mice exhibited a higher DAI compared to LysMCre mice when kept 
were on regular drinking water (Figure 24B). Even without statistical significance, this phenotype 
recapitulated the defective resolution in LysMCre;Hif2αfl/fl mice observed in the acute colitis model 
(Figure 8G). Even though the shorter colon lengths of LysMCre;Hif2αfl/fl mice would suggest more 
severe inflammation (Figure 24C), comparable gene expression of genes encoding pro-
inflammatory cytokines in the gut (Figure 24D), body weight change, and DAI indicated a none-
to-mild effect of myeloid HIF-2α on the pathology of DSS-induced chronic colitis. This conclusion 
was further supported by flow cytometry analysis, which also did not detect any major differences 
in myeloid and lymphoid cell populations in the lamina propria between the two cohorts (Figure 
25). Collectively, these data suggest myeloid HIF-2α is not required for DSS-induced chronic 
colitis. 
Loss of myeloid ARNT mildly alleviates TPA-induced acute skin inflammation 
The phorbol ester 12-O-tetradecanoylphorbol-13-acetate (TPA) is a small molecule drug 
that activates the signal transduction enzyme protein kinase C (PKC) (Castagna et al. 1982, 
Blumberg 1988), and has been widely used as a carcinogen and inflammatory stimulus for mouse 
skin (Iversen 1985, Stanley et al. 1991). A previous study by our lab reported that myeloid HIF-2α 
was required for TPA-induced skin inflammation (Imtiyaz et al. 2010). Therefore, we further 
examined the role of pan-HIF in this acute inflammation model using LysMCre and 
LysMCre;Arntfl/fl mice. Mice from these two cohorts were painted with 2.5µg of TPA on one ear 
and an equal-volume of acetone as vehicle control on the other. Tissue biopsy was taken 24 
hours post-treatment for the assessment of tissue thickness, weight, histology, pro-inflammatory 
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cytokine gene expression, and leukocyte infiltration. Mice with myeloid ARNT deficiency exhibited 
a moderately lower fold increase in ear thickness and weight upon TPA treatment (Figure 26A-C), 
suggesting less edema at the inflamed site. TPA also induced the gene expression of several 
pro-inflammatory cytokines (IL-1β, IL-6, Il-12α and TNFα), which was suppressed for most when 
ARNT was depleted in myeloid cells (Figure 26D). However, similar to the mild alleviation of 
edema, suppression of pro-inflammatory cytokine gene expression was not remarkable, 
indicating HIFs may be minor contributors to the pathology of this skin inflammation model.  
 To examine whether myeloid cell infiltration was altered by the absence of ARNT, we 
applied flow cytometry analysis of immune cells isolated from inflamed ear tissue. Compared to 
acetone-treated ears, ears treated with TPA exhibited increased numbers of immune cells 
(CD45+) per mg of ear tissue (Figure 27A), and myeloid ARNT deficiency further promoted 
immune cell infiltration (Figure 27A). Among the TPA-induced leukocyte infiltration, neutrophils 
and monocytes showed significantly increased percentages in CD45+ cells (Figure 27B, 27D), 
while the percentage of dendritic cells remained comparable and the percentage of macrophages 
decreased significantly compared with acetone-treated controls (Figure 27C, 27E). This is 
consistent with acute inflammation where neutrophils and inflammatory monocytes are often the 
first line of cells recruited to the inflammation site. This trend was also observed when cells 
counts of each population were normalized to tissue weight (Figure 27B-E). Of note, 
LysMCre;Arntfl/fl mice had higher cell counts per mg of ear tissue of all four myeloid cell 
populations when compared to LysMCre mice upon TPA stimulation (Figure 27B-E), suggesting 
that loss of myeloid ARNT may promote myeloid cells infiltration in this model.  
Interestingly, in this skin inflammation model, we noticed a considerable subpopulation of 
neutrophils were positive for CD11c, which can be further divided based on F4/80 expression 
(Figure 28A). Cells that were CD11c+ and F4/80+ exhibited decreased percentage upon TPA 
treatment (Figure 28A, 28B, and 28E). However, loss of myeloid ARNT not only prevented the 
percentage decline of these cells, but also elevated cell numbers per mg of ear tissue (Figure 
28A, 28B, and 28E), bringing the ratio of CD11c+/F4/80+ vs. CD11c+/F4/80- populations similar to 
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that in acetone-treated mice (Figure 28B, 28D, and 28E). Whether this ratio is important for skin 
inflammation and the exact function(s) of these subpopulations remains unknown. 
Given the mildly alleviated inflammation in the acute skin inflammation model, we next 
sought to examine the role of pan-HIF activity in chronic disease. LysMCre and LysMCre;Arntfl/fl 
mice were given 2.5µg TPA , with acetone as vehicle control, repeatedly for three times on Day 0, 
4, and 8 before assessment of edema as well as inflammation on Day 12. In contrast to the acute 
model, myeloid ARNT deficiency did not provide any recovery benefit to these mice, manifested 
by comparable fold change in ear thickness and weight (Figure 29A-B). Collectively, these data 
suggest a minor role for myeloid HIF signaling solely in the acute phase of skin inflammation.   
Myeloid ARNT is dispensable for thioglycollate-induced peritonitis and LPS-induced 
endotoxemia 
Two additional acute inflammation models were tested to characterize the importance of 
pan-HIF activity in mediating inflammatory responses in vivo. We first induced peritoneal 
inflammation by injecting LysMCre and LysMCre;Arntfl/fl mice with thioglycollate (TG), and 
measured immune infiltrates in the peritoneal cavity four hours and four days post-injection. 
Consistent with other reports, neutrophils responded rapidly to the stimulus, shown by their high 
percentage of CD45+ cells four hours post-injection (Figure 30A), while macrophages peaked 
four days post-injection (Figure 30B). However, no significant difference was observed between 
LysMCre and LysMCre;Arntfl/fl mice. The lymphoid compartment also did not exhibit noticeable 
changes. Therefore, myeloid ARNT is not required for immune cell migration in this TG-induced 
peritonitis model.  
The second model was an endotoxemia induced by lipopolysaccharide (LPS) injection, 
causing rapid systemic inflammation similar to sepsis. LysMCre;Arntfl/+ and LysMCre;Arntfl/fl mice 
were given 15 mg/kg of LPS by intraperitoneal injection and monitored closely. Complete loss of 
two Arnt alleles did not provide any survival advantages compared with mice with one Arnt allele 
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remaining (Figure 31), suggesting that myeloid ARNT may not be the determining factor for 
survival in this endotoxemia model.  
DISCUSSION 
 In this chapter, we demonstrate that myeloid HIFs adopt different roles in various 
inflammatory diseases. Myeloid HIF deficiency exacerbates tumor burden and progression of 
murine colitis-associated cancer, and mildly suppresses TPA-induced skin inflammation. 
However, in other inflammatory models, myeloid HIFs are dispensable for leukocyte infiltration in 
TG-induced peritonitis and animal survival in LPS-induced endotoxemia. These data reinforce 
that function(s) of each HIF-α subunit in myeloid cells is disease-dependent and introduce many 
intriguing questions to be addressed further. 
 Based on the protective effects of myeloid HIF-2α loss and HIF inhibition by ACF 
treatment in the same AOM/DSS induced CAC model (Shay et al. 2014, Imtiyaz et al. 2010), we 
initially predicted that depletion of both myeloid HIF-αs would mitigate tumor growth and 
progression. Surprisingly, our study revealed greater tumor burden and more advanced tumor 
progression when both HIF-1α and HIF-2α were absent in myeloid cells. Since ACF treatment 
can inhibit HIF signaling in colonic cells other than myeloid cells, it is possible that myeloid HIF 
signaling acts to suppress tumor growth, but is not enough to override the pro-tumor effects of 
HIF signaling in other cells types, such as colonic epithelial cells (Ma et al. 2017, Xue and Shah 
2013, Xue et al. 2012). Again, this highlights a similar theme as in the colitis model where the role 
of HIF signaling is highly cell type-specific. Additionally, myeloid HIF-2α deficiency did not limit 
tumor burden as previously described (Imtiyaz et al. 2010); instead it slightly increased tumor 
burden, although this was not statistically significant (Figure 20). The discrepancy may be 
attributed to the differences in genetic background. Rather than using mice with a mixed 129/Sv × 
C57BL/6 genetic background, we used mice with a pure C57BL/6 background, which are known 
to be more susceptible to DSS-induced colitis compared with 129/Sv mice (Knod et al. 2014).  
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We found that the numbers of TAMs were comparable in control mice and mice with 
myeloid HIF deficiency, while ACF treatment decreased macrophage infiltration (Shay et al. 2014). 
This may indicate a cell-extrinsic control of TAM migration and invasion by HIF signaling in other 
colonic cells, and require further investigation. Additionally, the fact that significant differences in 
tumor burden and progression were accompanied by comparable TAM presence let us to wonder 
whether functional phenotypes of these cells were more important than numbers, similar to what 
was observed in the acute colitis model: numbers of macrophages were almost identical during 
colitis resolution in LysMCre and LysMCre;Arntfl/fl mice, while LysMCre;Arntfl/fl macrophages 
exhibited a less pro-resolving gene expression profile (Figure 13). Genetic profiling of these 
TAMs may help to confirm whether they are true contributors to CAC pathology and provide 
insights regarding how HIF signaling regulates their functions in this particular setting. 
The specific survival disadvantage of LysMCre;Hif2αfl/fl mice in the AOM/DSS induced 
CAC model is an interesting observation. However, the result that myeloid HIF-2α was 
dispensable for DSS-induced chronic colitis suggests that myeloid HIF-2α deficiency did not 
contribute to the lower survival rate by exacerbating inflammation. Instead, loss of myeloid HIF-2α 
may render animals more susceptible to carcinogen, AOM, or the combination of AOM and DSS. 
Consistent with previous studies about each HIF-α isoform (Imtiyaz et al. 2010, Cramer et 
al. 2003), we also found less severe skin inflammation when ARNT was depleted from myeloid 
cells, manifested by slightly reduced ear edema. However, in contrast to the decrease in 
leukocyte and neutrophil infiltration observed in these previous studies, mice with myeloid ARNT 
deficiency exhibited higher number of CD45+ cells and neutrophils normalized to the weight of ear 
tissue. Moreover, Ly6C+ monocytes, another pro-inflammatory myeloid population, also showed 
almost 2.5-fold increase in LysMCre;Arntfl/fl mice compared with control mice. Alleviated 
inflammation accompanied by a higher presence of pro-inflammatory myeloid cells is quite 
counterintuitive. Furthermore, a high number of neutrophils were CD11c+ in this skin inflammation 
model, which was not seen in the intestine or the spleen (data not shown). This CD11c+ 
subpopulation can be further segregated based on F4/80 expression, which have not been 
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reported in any literature so far. Interestingly, TPA treatment increased the proportion of 
CD11c+,F4/80- cells and significantly decreased the proportion of CD11c+,F4/80+ cells out of total 
neutrophils, while their proportions in TPA-treated LysMCre;Arntfl/fl mice were comparable to 
acetone-treated mice. The ratio or balance of these two neutrophil subpopulations may be 
important for the in vivo inflammatory responses in this model and will require additional 
investigation. 
Finally, we revealed that HIF-α/ARNT is dispensable for leukocyte infiltration in a 
peritonitis model and animal survival in an endotoxemia model. Myeloid HIF-2α deficiency has 
been shown to impair macrophage migration towards the site of peritonitis (Imtiyaz et al. 2010), 
which was not recapitulated in our study where myeloid pan-HIF activity was inhibited by ARNT 
depletion. HIF-1α in the myeloid compartment may oppose HIF-2α in these cells. However, the 
concomitant blockade of AhR activity by ARNT depletion is a more likely explanation for the 
discrepancy, given that AhR has been demonstrated to suppress Alum-induced peritonitis and 
the recruitment of neutrophils as well as Ly6C+ monocytes in this model (Huai et al. 2014). 
Similarly, the comparable survival of LysMCre;Arntfl/+ and LysMCre;Arntfl/fl mice may be attributed 
to the partial loss of ARNT in heterozygous mice. However, the inhibition of AhR activity is more 
likely contributing to the phenotype. In the study by Imtiyaz and colleague, the control group was 
also heterozygous LysMCre;Hif2αfl/+ mice, but LysMCre;Hif2αfl/fl mice exhibited significantly better 
survival, with 40% of mice alive 5 days after LPS injection. Mice with myeloid HIF-1α deficiency 
showed even lower mortality rate (~25%) for almost 5 days (Peyssonnaux et al. 2007). Therefore, 
we believe the heterozygous control in our study was not sufficient to account for the lack of 
significant survival differences. As reduced AhR activation has been linked to higher mortality in 
the same endotoxemia model (Bessede et al. 2014), depletion of ARNT, which inhibits AhR 
signaling, may override the protective effects of impaired HIF activity, resulting in the 100% 
mortality we observed within 40 hours after LPS injection. Experiments utilizing LysMCre and 
LysMCre;Hif1αfl/f;Hif2αfl/fl mice will be able to address these hypotheses by teasing apart the 
contribution from HIF-αs vs. AhR.   
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 In summary, this chapter further highlights the disease and tissue dependence of myeloid 
HIF-α functions. The opposing effects of AhR to HIFs in these models underscore the importance 
of developing more specific ways to target HIF pathways. 
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CHAPTER 4 
Concluding Remarks 
Myeloid cell hypoxic responses are a key component in the pathology of many 
inflammatory diseases, as inflammation is often accompanied by tissue hypoxia and dysregulated 
innate immunity (Eltzschig and Carmeliet 2011). Myeloid cells, essential contributors to innate 
immunity, preferentially accumulate within hypoxic regions and adapt to limited O2 via activation 
of HIF signaling (Murdoch, Muthana, and Lewis 2005). However, these HIF-mediated responses 
in macrophages and neutrophils do not always promote or suppress inflammation; it depends on 
the disease type, cell type, and phases of inflammation, as revealed by this body of work. 
Moreover, common (Cramer et al. 2003, Imtiyaz et al. 2010, Walmsley et al. 2005, Thompson et 
al. 2014), non-redundant (Cramer et al. 2003, Imtiyaz et al. 2010), and opposing functions 
(Takeda et al. 2010, Keith, Johnson, and Simon 2011) of HIF-1α and HIF-2α in myeloid cells (Lin 
and Simon 2016) add to the complexity of predicting clinical outcomes of HIF inhibition or 
activation. In order to expand our understanding of myeloid HIF signaling in particular pathologic 
conditions, this thesis utilized genetically engineered mouse models driven by highly myeloid 
specific LysMCre as an approach to more precisely investigate the roles of myeloid HIF-αs in 
settings of several acute and chronic inflammatory diseases. 
In Chapter 2, I demonstrated that myeloid HIF signaling promotes the resolution of acute 
intestinal inflammation. Depletion of ARNT from myeloid cells effectively repressed HIF-1α and 
HIF-2α mediated transcriptional activities in BMDMs. Disruption of myeloid HIF signaling had no 
effect on the onset of acute colitis, but resulted in significantly inefficient resolution of colonic 
inflammation in a DSS-induced acute colitis model. Importantly, this defect should be primarily 
attributed to HIF-1α and HIF-2α, given that the loss of either subunit in myeloid cells recapitulated 
the phenotype of myeloid ARNT depletion in this model. During the resolution phase, myeloid HIF 
deficiency led to increased infiltration of pro-inflammatory neutrophils and monocytes into 
diseased tissues. HIF-deficient macrophages also exhibited impaired functional conversion to a 
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protective, pro-resolving phenotype. Moreover, gut serum amyloid A levels were remarkably 
elevated upon loss of myeloid ARNT during the resolution phase of colitis. Collectively, these 
dysregulated processes may together contribute to defective resolution of colitis, providing 
additional insights into therapeutic approaches to treat IBD patients.  
In Chapter 3, I extended the investigation of HIF inhibition to colitis-associated cancer 
(CAC) and other inflammatory diseases. In an AOM/DSS-induced CAC model, tumor burden and 
progression were exacerbated only when both HIF-1α and HIF-2α were depleted from myeloid 
cells. Additionally, pan-HIF inhibition mildly alleviated edema in a TPA-induced skin inflammation 
model. However, infiltration of immune cells in a TG-induced peritonitis model and animal survival 
in a LPS-induced endotoxemia model appeared to be completely independent of myeloid HIF 
signaling. Collectively, these data add to our current understanding of myeloid HIF in these 
pathological conditions, reinforce diverse roles of myeloid HIF-α’s in various inflammatory 
diseases, and highlight that their functions depend on disease type.   
 Here, I will summarize some key implications that arise from this body of work and 
propose future studies to further extend our understanding of the crosstalk between hypoxia, HIF, 
myeloid cells and inflammation. 
Select the right HIF-α subunit 
HIF-1α and HIF-2α are the two best characterized HIF-α subunits, and govern key 
biological processes in myeloid cells under hypoxic or inflammatory stresses (Lin and Simon 
2016). Interestingly, these two subunits can share the same, but also sometimes elicit distinct 
effects in many pathological conditions (Keith, Johnson, and Simon 2012). For example, intestinal 
epithelial cell HIF-1α helps to ameliorate inflammation (Karhausen et al. 2004, Furuta et al. 2001, 
Hirota et al. 2010), while HIF-2α in the same cells worsens acute colitis (Xue et al. 2013). In a 
tumor setting, HIF-2α promotes neuroblastoma progression to an aggressive phenotype; however, 
high HIF-1α levels correlates with low tumor stage and a favorable patient prognosis (Holmquist-
Mengelbier et al. 2006, Noguera et al. 2009). Consistently, HIF-1α and HIF-2α can also exhibit 
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antagonistic functions in macrophages, e.g. nitric oxide (NO) production (Takeda et al. 2010); or 
shared functions, e.g. cytokine production (Cramer et al. 2003, Imtiyaz et al. 2010). The notion 
that HIF-1α and HIF-2α can adopt distinctive roles is further demonstrated in vivo by this body of 
work. In Chapter 2, I showed that HIF-2α has a less dramatic induction under hypoxia in BMDMs 
compared to HIF-1α, which was further reflected in vivo as a less impressive contribution of HIF-
2α, compared with HIF-1α, to colitis resolution. Regardless of HIF-1α being the dominant isoform, 
both subunits impact proper resolution of intestinal inflammation. TPA-induced skin inflammation 
is another inflammatory condition where inhibition of either HIF-1α or HIF-2α, or both, helped to 
mitigate edema of ear tissue. However, myeloid HIF-1α and HIF-2α displayed divergent roles in a 
CAC model, where myeloid HIF-1α loss correlated with more advanced disease progression, and 
HIF-2α deficiency exacerbated colonic inflammation. Future studies will be required to identify the 
disease type-specific factors dictating myeloid HIF-α functions and the underlying molecular 
programs through which the two subunits cast similar or distinct effects. Nevertheless, my in vivo 
data, together with previous studies, stress the importance of selecting the appropriate HIF-α 
subunit(s) to target in different types of disease for the optimal outcome.  
Intervene at the right time 
 Inflammation is a highly dynamic and tightly regulated process, with onset of the reaction 
to clear pathogens and a resolution program to ensure restoration of homeostasis. Non-resolving 
acute inflammation could eventually develop into persistent chronic inflammation (Soehnlein and 
Lindbom 2010, Ortega-Gomez, Perretti, and Soehnlein 2013). Macrophages are particularly 
plastic and can adopt multiple functional phenotypes depending on their surrounding 
microenvironment (Sica and Mantovani 2012, Shapouri-Moghaddam et al. 2018, Galli, 
Borregaard, and Wynn 2011). Unsurprisingly, macrophages exhibit distinct phenotypes at 
different stages of inflammatory diseases (Soehnlein and Lindbom 2010). My work provides two 
great examples demonstrating how crucial it is to intervene with myeloid HIF signaling at the 
correct disease stage. In an acute colitis model, activation of myeloid HIF signaling is essentially 
dispensable for the onset of inflammation, but necessary for the proper resolution of colonic 
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inflammation. The requirement of HIF signaling for macrophages to convert to a pro-resolving 
phenotype in a timely manner is very likely underlying the temporal dependence of myeloid HIF in 
acute colitis. Another example is the TPA-induced skin inflammation, where myeloid HIF 
deficiency alleviates the acute disease but does not affect pathology of chronic skin inflammation. 
Future studies with careful temporal characterization of myeloid HIFs are needed to provide 
useful insights into the optimized timing of pharmacological intervention, and a more detailed 
understanding of how myeloid HIFs mediate molecular decisions of inflammation timing. 
Target the right cells 
 An inflammatory site harbors myriad cells, all of which experience low O2 stress 
(Eltzschig and Carmeliet 2011). HIF-mediated hypoxic responses differ between cell types and do 
not necessarily dictate all to adopt a pathogenic or protective phenotype. For example, ACF, a 
potent inhibitor of HIF-α/ARNT dimerization, prevents tumor progression in a CAC model in vivo, 
and blocks HIF signaling in both macrophages and colorectal cancer cell lines in vitro (Shay et al. 
2014). However, repression of HIF signaling in macrophages and cancer cells likely opposes 
each other in terms of disease outcome. Utilizing cell type-specific genetic mouse models, we 
and others have demonstrated that myeloid deficiency of HIF-1α and HIF-2α exacerbates CAC 
burden and progression, while loss of intestinal epithelial HIF-2α facilitates to suppress CAC 
growth (Ma et al. 2017, Xue and Shah 2013, Xue et al. 2012). In this particular situation, cancer 
cell specific-HIF inhibition may actually result in more effective tumor suppression than targeting 
all cells in the colon. Similarly in the setting of colitis, HIF-1α and HIF-2α antagonize each other in 
the intestinal epithelial cells (Karhausen et al. 2004, Furuta et al. 2001, Hirota et al. 2010, Xue et 
al. 2013); while pan-HIF activation in myeloid cells was shown in Chapter 2 to promote resolution 
of acute colitis. Therefore, a pan-HIF activating approach, i.e. administration of PHD inhibitors, 
specific to myeloid cells may possess greater potential to suppress inflammation. However, we 
should take into account the technical difficulty of cell type-specific drug delivery as a major 
hindrance to clinical practice.  
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AhR: confounding factor and alternative target 
AhR is another ARNT binding partner that has been implicated in mediating inflammatory 
responses (Mulero-Navarro and Fernandez-Salguero 2016). It has the potential to contribute to 
the phenotypes observed in studies utilizing ARNT depletion in particular as an approach to study 
HIF-α functions. In the acute colitis model, we ruled out AhR as a major contributor to resolution 
of colonic inflammation, consistent with the finding from a previous study using mice with myeloid-
specific depletion of AhR in the same model (Chinen et al. 2015). However, in the peritonitis and 
endotoxemia models, AhR may be the major confounding factor to the phenotypic discrepancy 
we observed between ARNT and individual HIF-α loss. AhR may represent as a more viable 
therapeutic target than HIF for these specific diseases, given its unique ligand binding ability 
towards a broad range of xenobiotics (Mulero-Navarro and Fernandez-Salguero 2016, Pandini et 
al. 2007). Future experiments using LysMCre;Hif1αfl/fl;Hif2αfl/fl mice will help to address these 
hypotheses, and the comparison between ARNT- and pan-HIF depletion will prove useful in 
teasing apart the effects from HIF and AhR.  
Lipid metabolism in colonic macrophages 
 Dysregulated lipid metabolism is another feature of some inflammatory scenarios. In 
particular, obesity and atherosclerosis are the two best studied diseases for crosstalk between 
lipid metabolism, macrophages and inflammation (Lin and Simon 2016). Lipid-laden 
macrophages, known as foam cells, facilitate initiation and progression of atherosclerosis (Moore, 
Sheedy, and Fisher 2013, Moore and Tabas 2011). Adipose tissue macrophages (ATMs) also 
adopt a pro-inflammatory phenotype in obese patients (Weisberg et al. 2003). Unsurprisingly, 
HIFs govern key molecular programs determining the phenotypes of these pathogenic 
macrophages in atherosclerosis and obesity (Lin and Simon 2016). In light of this evident link 
between inflammation and lipid metabolism, as well as the reported lipid abnormalities in IBD 
patients (Agouridis, Elisaf, and Milionis 2011, Ungaro et al. 2017), we are excited to discover 
“transport of lipid” and “fatty acid metabolism” as the two most significantly upregulated biological 
processes in LysMCre;Arntfl/fl lamina propria macrophages based on IPA of our microarray data 
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(Table 2). Some of the upregulated genes under these two biological processes have been 
shown to facilitate inflammation. For example, Fabp4 encodes a fatty acid binding protein, and 
deletion of this gene in macrophages is sufficient to protect mice from developing atherosclerosis 
and dyslipidemia (Makowski et al. 2001). We believe that disrupted lipid metabolism represents a 
highly promising mechanism through which myeloid HIF-α subunits contribute to the defective 
resolution of acute colitis.  
Concerted efforts have enabled development of many HIF-α inhibitors (e.g. ACF) and 
stabilizers (e.g. PHD inhibitors). In recent years, more and more inhibitors that are highly specific 
to either HIF-1α or HIF-2α have made into preclinical or even clinical trials (Wigerup, Pahlman, 
and Bexell 2016). These achievements empower us with tools that can either suppress or 
activate HIF signaling in a broad range of diseases. I believe that disease-by-disease 
characterization of HIF functions in a temporally-regulated and cell type-specific approach would 
truly accelerate and expand the application of these elegantly designed drugs in the treatment of 
patients afflicted by chronic inflammation and cancer.  
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MATERIALS AND METHODS 
Mice  
The Arnt, Hif1α and Hif2α conditional alleles were crossed with the LysM-Cre allele 
(Clausen et al. 1999) to achieve myeloid-specific Arnt, Hif1α or Hif2α conditional knockout mice. 
Mice with Hif1a conditional allele on a C57BL/6 background were purchased from Jackson 
Laboratory (Bar Harbor, ME). LysMCre;Hif2αfl/fl mice were generated and described in a previous 
study (Imtiyaz et al. 2010). Ever since this study, we have backcrossed Hif2αfl/fl mice with 
C57BL/6 mice sufficiently to ensure a similar background to other strains. Arntfl/fl mice with a 
mixed background of C57BL/6 and 129svJ were also backcrossed with C57BL/6 mice sufficiently 
before crossed with LysMCre mice. All animal procedures were performed in accordance with 
NIH guidelines and were approved by the Institutional Animal Care and Use Committee of the 
University of Pennsylvania. 
Induction of colitis and clinical scoring 
For acute colitis model, dextran sulfate sodium (DSS) (MW 36-50 kDa, MP Biomedicals, 
Santa Ana, CA) was administered orally in drinking water at 3% (w/v) concentration for 5 days 
followed by normal drinking water for 3 days. For chronic colitis model, mice were given 3 cycles 
of 2% (w/v) DSS for 5 days followed by normal drinking water for another 5 days after each DSS 
treatment. Mice of both genotypes (LysMCre vs. LysMCre;Arntfl/fl for acute colitis; and LysMCre 
vs. LysMCre;Hif2αfl/fl for chronic colitis) were housed in the same cages to minimize potential 
confounding influences from differing microbiomes. Body weight, stool consistency, and fecal 
blood were monitored and recorded daily for each mouse. Disease Activity Index (DAI) was 
calculated as the sum of scores for body weight loss, stool consistency, and fecal blood. These 
three parameters were scored as following (Melgar, Karlsson, and Michaelsson 2005, Qiu et al. 
2011): 0, no weight loss or less than 1% weight loss, normal stool pellets, negative Hemoccult 
test (Beckman Coulter, Brea, CA); 1, 1%-5% weight loss, slightly loose feces; 2, 5%-10% weight 
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loss, lose feces, positive Hemoccult test; 3, 10%-20% weight loss, watery diarrhea; 4, more than 
20% weight loss, positive Hemoccult test, and visible fecal and rectal blood. 
Histopathology assessment of DSS-induced acute colitis 
Colons ranging from cecum to rectum were cut longitudinally, fixed in 4% 
paraformaldehyde/PBS (4°C overnight), and embedded in paraffin for sectioning. Five-µm -thick 
sections were cut and stained with hematoxylin and eosin and scored in a double-blind manner. 
Tissue sections were scored for loss of mucosal architecture, cellular infiltration, crypt abscess 
formation, Goblet cell depletion, and tissue affected, yielding a total histopathology score. Loss of 
mucosal architecture was scored 0 to 3 for absent, mild, moderate, and severe with loss of entire 
crypts. Cellular infiltration was scored 0 to 3 for absent, mild, moderate, and extensive. Crypt 
abscess formation was scored 0 or 1 for absent or present. Goblet cell depletion was scored 0 or 
1 for absent or present. Percentage of tissue affected was scored 0 to 3 for absent, >10%, 20-
30%, and 40-50%. The sum of these values for each mouse gave a total histopathology score. 
Azoxymethane (AOM)/DSS induced colitis-associated colorectal cancer 
The AOM/DSS induced CAC model was performed as previously described (Hongxia). 
Eight- to nine-week-old male and female mice received a single intraperitoneal injection of 12.5 
mg/kg AOM on Day 0 followed by 3 cycles of DSS in drinking water starting on Day 5 (cycle 1: 
1.8% DSS for 5 days; cycle 2: 2.0% DSS for 7 days, cycle 3: 2.0% DSS for 7 days) with 2 weeks 
of regular drinking water in between each cycle and after the third cycle till the end of this 
experiment. The end point was set to 14 weeks, when mice were sacrificed. Some mice 
exhibiting severe symptoms were sacrificed along the course of experiment before 14 weeks. 
Colons were flushed with PBS and cut open longitudinally for counting and measurement of 
polyps. Polyps were counted across the whole colon from rectum to cecum. Their diameter was 
measured using a digital caliper (Thermo Fisher Scientific, Waltham, MA). Tumor grading was 
performed as previously described (Hongxia). Inflammation was graded as mild, moderate or 
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severe. Tumor-associated macrophages were counted as F4/80+ cells on a ×20 field for 3 fields 
using TMARKER (Nexus, Zürich, Switzerland). 
TPA-induced ear cutaneous inflammation 
TPA-induced ear cutaneous inflammation was conducted as described previously 
(Cramer et al. 2003). Male mice that were 9-week old were used in this experiment. Briefly, for 
each mouse, one ear was painted with 2.5 µg of TPA in acetone and the other ear was treated 
similarly with acetone as vehicle control. The mice were sacrificed 24 hours after the TPA 
application. Tissue biopsy with the same surface area was captured and used for assessment of 
edema (ear tissue thickness and weight), and then prepared for H&E, gene expression or 
leukocyte infiltration by flow cytometry.  
Thioglycollate-induced peritonitis 
Female mice that were 8-week old were injected intraperitoneally with 1 mL of 3% 
thioglycollate, and were sacrificed 4 hours and 4 days after the inject for peritoneal exudate cells 
harvest. These cells were immediately subject to flow cytometry analysis.   
LPS-induced endotoxemia 
LPS-induced endotoxemia was conducted as described previously (Peyssonnaux et al. 
2007). Male mice that were 14-week old were injected intraperitoneally with 15mg/kg of LPS, and 
monitored for survival. Survival data were analyzed by the construction of Kaplan-Meier plots.  
Isolation of lamina propria cells 
Lamina propria cells were isolated using a modified version of previously described 
protocols (Weigmann et al. 2007, Zaph et al. 2007). Briefly, colons were cut open longitudinally 
and shaken in medium with 1 mM EDTA and 1 mM DTT twice for 20 minutes each at 37°C. The 
remaining tissue was further digested with 0.5mg/mL Collagenase/Dispase (Roche, Basel, 
Switzerland) and 0.05 mg/mL (92.15 Kunitz unit/mL) DNase I (Sigma-Aldrich, St. Louis, MO) for 
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40 minutes at 37°C with agitation. Cells were then harvested by passing the suspension through 
a 70-μm cell strainer (Corning, Corning, NY). Single cell suspensions were later analyzed ex vivo 
by flow cytometry. 
Flow cytometry 
Single cells suspensions were blocked with Mouse BD Fc BlockTM (BD Biosciences, 
Franklin Lakes, NJ) for 10 minutes and then stained in FACS buffer (PBS with 4% FBS and 2 mM 
EDTA) with the following fluorochrome-conjugated antibodies: APC-conjugated anti-CD19 (1D3, 
#550992, 1:200), APC-Cy7-conjugated anti-CD4 (GK1.5, #552051, 1:200), PE-Cy7-conjugated 
anti-CD8a (53-6.7, #552877, 1:200), FITC-conjugated anti-CD45 (30-F11, #561088, 1:100), 
V450-conjugated anti-CD3e (500A2, 560801, 1:100), APC-Cy7-conjugated anti-Ly6C (AL-21, 
#560596, 1:100), PE-Cy7-conjugated anti-CD45 (30-F11, #552848, 1:100), V450-conjugated 
anti-CD11c (HL3, #560521, 1:100), PerCP-Cy5.5-conjugated anti-CD11b (M1/70, #561114, 
1:100), AF700-conjugated anti-Ly6G (1A8, #561236, 1:100) (from BD Biosciences); PE-
conjugated anti-F4/80 (BM8, #12-4801, 1:100) (from eBioscience, San Diego, CA). Viability was 
determined by staining cells with LIVE/DEADTM Fixable Aqua Dead Cell stain, 1:300 (Thermo 
Fisher Scientific). Flow cytometry was performed on a LSR A flow cytometer (BD Biosciences), 
and data were analyzed using FlowJo software. 
Colonic explant supernatant collection and ELISA 
A 0.5 cm-long colon segment was collected about 1 cm from the rectum from each well-
flushed mouse colon. These colon segments were cultured in 24-well plates containing 0.6 mL of 
complete tissue culture medium (DMEM with 25 mM HEPES, 0.05 mM 2-mercaptoethanol, 2 mM 
L-Glutamine, 100 U/mL Penicillin, 100 μg/mL Streptomycin, and 10% FBS) for 24 hours till cell-
free culture supernatant was collected. The collected supernatants were then subject to 
quantification of cytokine levels using the following ELISA kits: Mouse IL-1 beta/IL-1F2 DuoSet 
ELISA kit (#DY401-05), Mouse IL-6 DuoSet ELISA (#DY406-05), Mouse CXCL1/KC DuoSet 
ELISA (#DY453-05), Mouse Serum Amyloid A DuoSet ELISA (#DY2948-05), Mouse Cytokine 
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Antibody Array, Panel A (#ARY006) (from R&D Systems, Minneapolis, MN), and Mouse SAA-3 
ELISA (#EZMSAA3-12K) (from Millipore Sigma, Burlington, MA). 
Microarray analysis 
Total RNA was extracted from flow cytometry-sorted lamina propria macrophages from 
LysMCre and LysMCre;Arntfl/fl mice using TRIzolTM LS Reagent (Thermo Fisher Scientific). Total 
RNA quality control tests were determined using BioAnalyzer 2100 (Agilent) and Nanodrop 
spectrophotometry (Thermo Fisher Scientific). The cDNA was prepared, labeled, and hybridized 
to Affymetrix GeneChip, mouse gene 2.0 using GeneChip WT PLUS Reagent Kit (Affymetrix, 
Santa Clara, CA). Hybridized chips were scanned with GeneChipTM Scanner 3000 7G 
(Affymetrix).  Affymetrix Command Console and Expression Console (Thermo Fisher Scientific) 
were used to quantitate expression levels for targeted genes; default values provided by 
Affymetrix were applied to all analysis parameters. Transcriptomic analysis was carried out using 
Partek Genomic Suite 6.1 (Partek, Inc., St. Louis, MO). Robust MultiArray Average (RMA) 
(Irizarry et al. 2003) was used for normalization of the raw probe intensity data. Significance 
Analysis of Microarrays (SAM) (Tusher, Tibshirani, and Chu 2001) was applied to compare 
LysMCre and LysMCre;Arntfl/fl samples. The magnitude of d score, the T-statistic value used in 
SAM, scales with statistical significance. A false discovery rate (q-value) was estimated by SAM 
based on a null distribution for the d score by permuting the samples with respect to LysMCre 
and LysMCre;Arntfl/fl classes. Differentially expressed genes were defined as those having fold 
change above or below 1.5 and q value < 0.05.  
Generation and culture of bone marrow-derived macrophages (BMDMs) and neutrophils 
(BMDNs) 
Bone marrow cells were isolated from femurs and tibias of LysMCre and LysMCre;Arntfl/fl 
mice. After a quick incubation in ammonium-chloride-potassium (ACK) lysing buffer (Lonza, Basel, 
Switzerland) to remove red blood cells, the remaining bone marrow cells were cultured in BMDM 
medium (DMEM with 20% heat-inactivated Hyclone FBS, 30% L929 conditioned medium, 1X 
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Antibiotic-Antimycotic, 2 mM L-Glutamine, and 0.055 mM 2-mercaptoethanol) for 5 day on non-
treated tissue culture plates before passaging. To obtain BMDNs, EasySep™ Mouse Neutrophil 
Enrichment Kit (STEMCELL Technologies, Vancouver, Canada) was used for negative selection 
of neutrophils from bone marrow cells after lysis by ACK lysing buffer. BMDNs were analyzed 
immediately or cultured in neutrophil culture medium (RPMI 1640 with 10% FBS, 100 U/mL 
Penicillin and 100 μg/mL Streptomycin) for up to 24 hours before analysis. 
Neutrophil viability/apoptosis assessments 
Right after isolation of neutrophils from bone marrow cells using EasySep™ Mouse 
Neutrophil Enrichment Kit (STEMCELL Technologies), total number of viable cells was 
determined by cell counting with Trypan Blue. Same number of viable neutrophils was then 
cultured in neutrophil culture medium (RPMI 1640 with 10% FBS, 100 U/mL Penicillin and 100 
μg/mL Streptomycin) for 24 hours under normoxia (21% O2) or hypoxia (0.5% O2) before another 
viability analysis. Percentage viability was taken as percentage of viable neutrophils after 24-hour 
culture out of viable neutrophils seeded. Caspase-Glo® 3/7 assay (Promega, Madison, WI) was 
used with these cells at these two time points to assess apoptosis.  
Immunohistochemistry 
Immunohistochemistry was performed on sections from paraffin-embedded samples 
using VECTASTAIN Elite ABC HRP Kit (#PK-6100, Vector Laboratories, Burlingame, CA). Rat 
anti–mouse F4/80 primary antibody (#ab6640, Abcam Inc., Cambridge, MA) was used at a 1:100 
dilution (10 µg/mL). Vector Laboratories biotinylated anti-rat IgG was used as the secondary 
antibody at a 1:200 dilution. Sections were incubated with DAB substrate (Vector Laboratories) 
and counterstained with hematoxylin for nuclei. 
Quantitative RT-PCR 
Total RNA was isolated from colon tissues, macrophages derived from colon, BMDMs, 
and BMDNs using the RNeasy Mini Kit (Qiagen, Hilden, Germany). For colon tissues, BMDMs, 
92 
 
and BMDNs, cDNA was synthesized using a High-Capacity RNA-to-cDNA Master Mix (Applied 
Biosystems, Foster City, CA). PCR reactions were performed using Taqman Universal PCR 
reagents mixed with indicated cDNAs and Taqman primers in a ViiA7 Real-Time PCR system 
(Applied Biosystems). Expression levels were normalized to Hprt (Mm01318743_m1). The 
following Taqman primers were used in this study: Arnt (Mm00507836_m1), Adm 
(Mm00437438_g1), Vegfa (Mm01281449_m1), Ldha (Mm01612132_g1),  Pgk1 
(Mm00435617_m1), Arg1 (Mm00475988_m1), Serpine1 (MM00435860_M1), Il1b 
(Mm00434228_m1), Il6 (Mm00446190_m1), Il12a (Mm00434169_m1), Tnf (Mm00443258_m1), 
Cxcl10 (Mm00445235_m1), Cxcl12 (Mm00445553_m1), Cxcl13 (Mm04214185_s1), Ccl4 
(Mm00443111_m1), Ccl5 (Mm01302427_m1), Cyp1a1 (MM00487218_M1), Ugt1a1 
(Mm02603337_m1), Cxcr2 (MM99999117_S1), Il23a (Mm01160011_g1), Chi3l3 
(Mm00657889_mH), Mrc1 (Mm00485148_m1), and Retnla (Mm00445109_m1). For 
macrophages isolated from colon, due to limited amount of mRNA, anti-sense RNA (cRNA) 
generated in preparation for microarray analysis using GeneChip WT PLUS Reagent Kit 
(Affymetrix) was used to generate cDNA. PCR reactions were performed in a ViiA7 Real-Time 
PCR system using Sybr Green PCR Master Mix (Invitrogen, Carlsbad, CA) with following primers: 
mouse Saa1 (Forward 5’ to 3”: ACACCAGGATGAAGCTACTCACCA; Reverse 5’ to 3’: 
CCCTTGGAAAGCCTCGTGAACAAA), mouse Saa2 (Forward 5’ to 3”: 
TGGCTGGAAAGATGGAGACAA; Reverse 5’ to 3’: AAAGCTCTCTCTTGCATCACTG), mouse 
Saa3 (Forward 5’ to 3”: TGCCATCATTCTTTGCATCTTGA; Reverse 5’ to 3”: 
CCGTGAACTTCTGAACAGCCT), mouse Ptges1 (Forward 5’ to 3’: 
GGATGCGCTGAAACGTGGA; Reverse 5’ to 3’: CAGGAATGAGTACACGAAGCC), mouse 
Ptges2 (Forward 5’ to 3’: AAGGCCATGAATGACCAGGG; Reverse 5’ to 3’: 
TGTTCGGTACACGTTGGGAG), and mouse Ptgs2 (Forward 5’ to 3’: 
TTCAACACACTCTATCACTGGC; Reverse 5’ to 3’: AGAAGCGTTTGCGGTACTCAT).   
Western blot analysis 
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BMDMs were lysed with RIPA buffer containing protease inhibitor (Thermo Fisher 
Scientific). Cells lysates were boiled in SDS sample buffer for 10 minutes, separated by SDS-
PAGE, transferred to nitrocellulose membranes, probed with primary antibodies overnight at 4°C, 
and then detected with horseradish peroxidase-conjugated secondary antibodies (Vector 
Laboratories) followed by exposure to ECL (PerkinElmer, Waltham, MA). The following antibodies 
were used at indicated concentration: rabbit anti-ARNT (#5537, 1:1000, Cell Signaling 
Technology, Danvers, MA), rabbit anti-HIF-1α (#10006421, 1:1000, Cayman Chemical, Ann 
Arbor, MI), rabbit anti-HIF-2α  (#PA1-16510, 1:1000, Thermo Fisher Scientific), and mouse anti-β-
actin (#SC-47778, 1:4000, Santa Cruz Biotechnology, Dallas, TX). 
Eicosanoids analyses by liquid chromatography–mass spectrometry  
The analysis of eicosanoid metabolites in colonic explant supernatants and 
BMDMs/BMDNs culture media was performed as described previously for human plasma 
(Mazaleuskaya et al. 2016) with a few modifications. Culture medium samples (450 μl) were 
spiked with stable isotope-labeled internal standards ([d4]-PGE2 [5 ng]; [d4]-PGF2α [2.5 ng]; [d4]-
TxB2 [10 ng]; [d4]-LTB4 [1 ng]; [d5]-LTE4 [2.5 ng]; [d8]-5-HETE [2.5 ng]; [d8]-12-HETE [25 ng]; 
[d8]-15-HETE [1 ng]; [d8]-AA [2,500 ng]) (Cayman Chemical) in 1350 μl of acetonitrile. The 
samples were cleaned up by using Phree cartridges for phospholipid and protein removal (#8B-
S133-TAK from Phenomenex, Torrance, CA). Samples were then dried under a gentle stream of 
nitrogen at the ambient temperature and reconstituted with 30 μl of methanol. Before injection, 30 
μl of water was added to each sample and an aliquot of 20 μl was injected into a C18 UPLC 
column (ACQUITY UPLC BEH 2.1 × 150 mm × 1.7 μm) (Waters Corporation, Milford, MA) and 
eluted at a flow rate of 350 μl/min, with a linear gradient from 20% solvent B to 90% in 20 minutes. 
Mobile phase A consisted of water/mobile phase B, 95:5 (v/v), with 0.5% formic acid; mobile 
phase B consisted of acetonitrile/methanol, 95:5 (v/v), with 0.5% formic acid. Mass spectrometer 
parameters were optimized to obtain maximum sensitivity for respective product ions as 
described previously (Mazaleuskaya et al. 2016). The analysis was performed on a Waters 
ACQUITY Ultra Performance Liquid Chromatography system in-line with a Waters Xevo TQ-S 
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Triple Quadrupole Mass Spectrometer (Waters Corporation). The UPLC system directly 
interfaced with the negative-mode electrospray ionization (Lin et al.) source of the mass 
spectrometer using multiple reaction monitoring (MRM). Quantitation was done by peak area ratio 
and results were normalized to the sample volume.  
Statistical analysis 
Data were analyzed with GraphPad Prism 7. Unparied, two tailed t test was used for all 
single comparisons, and two-way ANOVA followed by Bonferroni’s correction was used for 
multiple comparisons. Data are presented as mean ± standard error of the mean (S.E.M.); values 
of p < 0.05 were considered statistically significant. 
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